









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Obeticholic	acid	 FXR	agonist	 III	 NCT02548351	
Cenicriviroc	 CCR2/CCR5	inhibitor	 III	 NCT03028740	
MSDC-0602K	 MPC	inhibitor	 IIb	 NCT02784444	
NGM282	 FGF19	analogue	 IIb	 NCT03912532	
Saroglitazar	 PPAR-α/γ	agonists	 II	 NCT03061721	
Resmetirom	 THR-ß	agonist	 III	 NCT03900429	
Tropifexor	 FXR	agonist	 IIb	 NCT02855164	
Aramchol	 SCD1	inhibitor	 III	 3rd	quarter	2019	




























































































CK-18,	adiponectin,	resistin		 0.73	 71.4%	 72.7%	 Not	externally	
validated		
Nice	Model	(158)	 ALT,	CK-18,	presence	of	MetS		 0.88	 84%	 86%	 Not	externally	
validated		






















































































Test	 Component	 AUROC	 Threshold	 Sensitivity	 Specificity	
Simple	Tests	








AST,	platelet	count	 0.67–0.94	 1.0	 27	 89	
BARD	(164,	172)	 Body	mass	index	(BMI),	AST/ALT	ratio,	diabetes	 0.77	 2.0	 89	 44	

































Test	 Component	 AUROC	 Fibrosis	
Stage	
Sensitivity	 Specificity	

































































































































































































































































































































































































































































































































































































































































































































system	introduced	the	concepts	of	‘grading’ activity and ‘staging’ fibrosis in	NAFLD, based	on	
the	 premise	 that	 disease	 activity	 assessment	 could	 be	more	 accurately	 summarised	 as	 a	
combination	 of	 steatosis,	 inflammation	 and	 ballooning	 determining	 the	 grade	 (48).	 The	




(0-3) and	hepatocellular	ballooning (0-2). Fibrosis	was	staged	from	0	to	4. ‘NASH’ was	defined	
as	steatosis	with	hepatocyte	ballooning	degeneration	and	 inflammation	+/− fibrosis	 (266).	
NASH	 was	 defined	 as	 NAS	 score	 >	 4.	 Staging	 of	 fibrosis	 follows	 a	 five-tier	 method	 (0-4)	
indicating	 progression	 of	 fibrosis	 from	 zone	 3	 peri-sinusoidal,	 to	 portal,	 to	 bridging	 to	





























































































































































































































































































































































































































































































































































































































































































































































































Steatosis	 -0.114	 0.171	 -0.130	 0.116	 -0.110	 0.185	 -0.135	 0.103	 -0.143	 0.083	 -0.068	 0.413	 -0.098	 0.235	
Ballooning	 -0.109	 0.188	 -0.64	 0.440	 -0.183	 0.026	 -0.177	 0.032	 -0.163	 0.049	 -0.007	 0.934	 -0.078	 0.349	
Lobular	
Inflammation	
-0.200	 0.015	 -0.100	 0.229	 -0.275	 0.001	 -0.180	 0.029	 -0.247	 0.003	 -0.080	 0.333	 -0.192	 0.020	









Steatosis	 Mean	CLDQ	score	 N	(%)	 Ballooning	 Mean	Value	 N	(%)	
0	 4.31	 1	(0.7%)	 0	 4.97	 44	(29.9%)	
1	 4.3	 33	(22.4%)	 1	 4.54	 72	(49%)	
2	 4.9	 79	(54%)	 2	 4.59	 31	(21.2%	











Mean	CLDQ	score	 N	(%)	 Fibrosis	 Mean	Value	 N	(%)	
0	 4.79	 27	(18.4%)	 0	 4.58	 29	(19.7%)	
1	 5.00	 69	(46.9%)	 1	 5.11	 29	(19.7%)	
2	 4.38	 49	(33.3%)	 2	 4.36	 28	(19%)	
3	 3.03	 2	(1.4%)	 3	 4.57	 40	(27.2%)	





















Gender	(Male)*	 47(55%)	 38	(45%)	 0.529	
Age	 53	+/-	12	 52	+/-	13	 0.928	
BMI	 36	+/-	5	 35	+/-	6	 0.039	
Obesity	 59	(95%)	 75	(88%)	 0.144	
T2DM*	 38	(61%)	 52	(61%)	 0.989	
ALT	 104+/-	72	 84	+/-	53	 0.142	
AST	 72	+/-41	 52	+/-	22	 0.003	
Albumin	 44	+/-3	 45	+/-	3	 0.260	
Platelet	count	 239	+/-71	 256	+/-	85	 0.299	
Cholesterol	 5.4	+/-1.3	 5.2	+/-	1.3	 0.421	
Histology	 	
Steatosis	(0/1/2/3)	 0/1/35/36	 1/32/44/8	 <0.0001	




Fibrosis	(0/1/2/3/4)	 0/6/16/30/10		 29/23/12/10/11	 <0.0001	
Patient	Reported	Outcomes	
CLDQ	 4.49	+/-	1.2	 4.90+/-	1.35	 0.038	
FIS	 86.93	+/-	33.23	 74.08	+/-	33.54	 0.010	
ESS	 8.59	+/-	5.3	 6.83	+/-	4.27	 0.010	





















	 Total	(n=147)	 NAFL		(n=85)	 NASH	(n=	62)	 p-value	
CLDQ	total	score	 4.73	+/-	1.3	 4.90	+/-	1.3	 4.49+/-	1.2	 0.038	
Abdominal	
symptoms	
5.24	+/-	1.6	 5.34	+/-1.7	 5.10	+/-1.5	 0.259	
Fatigue	 4.12	+/-	1.6	 4.41	+/-1.5	 3.73	+/-1.6	 0.010	
Systemic	
symptoms	
3.94	+/-1.1	 4.12	+/-1.1	 3.70	+/-1.1	 0.018	
Activity	 5.2	+/-	1.5	 5.47	+/-1.6	 4.87	+/-1.3	 0.004	
Emotional	
functioning	
4.6	+/-	1.6	 4.66	+/-1.7	 4.42	+/-1.6	 0.342	








































Male		 162	(53.3)		 85	(56.5)		 69	(51.9)		 6	(35.3)		 	0.82		
Age	(range)		 54	(17-77)		 53	(17-77)		 53	(21-75)		 61	(33-74)		 	0.05		
BMI	 33.3	(30.0;	37.5)	 35	(31.6;	38.7)	 31.9	(28.7;	36.3)	 31.2	(27.3;	37.0)	 <0.0001	
Obesity	 228	(75.0)		 134	(91.0)		 85	(63.9)		 10	(58.8)		 <0.0001		
T2DM		 156	(51.3)		 90	(61.0)		 52	(39.1)		 9	(52.9)		 <0.001		
Hypertension		 203	(66.8)		 87	(56.5)		 102	(76.7)		 14	(82.4)		 <0.001		
Hyperlipidemia		 177	(58.2)		 88	(57.1)		 83	(62.4)		 6	(35.3)		 0.07		
ALT		 73	(48;	110)		 93	(48;	109)		 81	(51;	110)		 33	(24;	61)		 <0.001		
AST		 50	(36;	69)		 60	(38;	71)		 51	(37;	68)		 29	(24;	54)		 <0.001		
γ-GT  84	(56;	162)		 92	(59;	164)		 80	(53;	161)		 82	(45;	223)		 0.5		
Albumin		 43	(40;	45)		 44	(43;	47)		 41	(39;	43)		 45	(43;	47)		 <0.001		
Platelet	count		 233	(183;	283)		 249	(190;	296)		 226	(183;	270)		 190	(176;	228)		 0.05		
HbA1c	 6.1	(5.5;	7.1)		 6.3	(5.75;	7.6)		 5.7	(5.3;	6.3)		 6.5	(6.2;	7.4)		 <0.001		
	
Histological	findings	





















































































CLDQ	overall	score			 4.99	(±1.2) 	 4.73	+/-	1.3	 5.27	(±1.1) 	 5.14	(±1.1)		 <0.01		
Abdominal	symptoms		 5.33	(±1.6) 	 5.24	+/-	1.6	 5.51	(±1.5) 	 4.76	(±1.6) 	 0.12		
Fatigue		 4.31	(±1.6) 	 4.12	+/-	1.6	 4.48	(±1.5) 	 4..64	(±1.7)		 0.09		
Systemic	symptoms		 5.09	(±1.3) 	 3.94	+/-1.1	 5.37	(±1.2) 	 5.35	(±1.2)		 <0.01		
Activity		 5.43	(±1.4) 	 5.2	+/-	1.5	 5.73	(±1.2) 	 5.12	(±1.4)		 <0.01		
Emotional	functioning		 4.93	(±1.5) 	 4.6	+/-	1.6	 5.30	(±1.3) 	 5.32	(±1.4)		 <0.001		






observed	in	the	subcategories	“fatigue” and “abdominal	symptoms” between	countries. 	
Overall,	the	general	QoL	data	extracted	from	the	CLDQ	assessment	has	shown	us	that	the	









































	 	 Rs	 P-Value	 Rs	 P-Value	 Rs	 P-Value	
CLDQ	 FIS	 -0.801	 <0.0001	 -0.797	 <0.0001	 -0.790	 <0.0001	
	 ESS	 -0.470	 <0.0001	 -0.467	 <0.0001	 -0.432	 0.001	
	 BIV2	 -0.744	 <0.0001	 -0.749	 <0.0001	 -0.731	 <0.0001	
FIS	 ESS	 0.541	 <0.0001	 0.616	 <0.0001	 0.408	 0.001	
	 BIV2	 0.760	 <0.0001	 0.790	 <0.0001	 0.722	 <0.0001	








































































































18	+/-	8	 0.240	 19	+/-	9	 20	+/-	
10	



























































Male*	 85	(56.5)		 0.114	 0.172	
Age	(range)		 53	(17-77)		 -0.087	 0.295	
BMI	 35	(31.6;	38.7)	 0.225	 0.006	
Obesity	 134	(91.0)		 0.114	 0.170	
T2DM	*	 90	(61.0)		 0.067	 0.419	
ALT		 93	(48;	109)		 0.010	 0.908	
AST		 60	(38;	71)		 0.119	 0.163	






























Male		 68	(60%)	 0.079	 0.405	 -0.323	 <0.0001	
Age	(range)		 55	+/-	12	 -0.001	 0.992	 0.007	 0.945	
BMI	 35	+/-	5	 0.222	 0.019	 -0.320	 0.001	
Obesity	 102	(90%)	 0.110	 0.250	 -0.186	 0.048	
T2DM		 67	(59%)	 0.033	 0.732	 -0.078	 0.412	
ALT		 93	+/-	64	 0.040	 0.676	 -0.042	 0.662	
AST		 61	+/-	35	 0.139	 0.156	 -0.182	 0.061	
Albumin		 44	+/-	3	 -0.146	 0.101	 0.181	 0.055	
Platelet	count		 241	+/-	75	 -0.004	 0.971	 -0.034	 0.722	
Steatosis	 1/26/58/28	 0.074	 0.438	 -0.107	 0.261	
Ballooning	 34/54/25	 0.158	 0.095	 -0.128	 0.179	
Lobular	Inflammation	 20/59/33/1	 0.231	 0.014	 -0.180	 0.056	














































Total	ESS	 0.834	 0.663	 0.130	
Ballooning	
Total	ESS	 0.828	 0.669	 0.129	
Lobular	inflammation	
Total	ESS	 1.416	 0.135	 0.202	
Fibrosis	




Total	FIS	 0.676	 0.939	 0.507	
Ballooning	
Total	FIS	 0.917	 0.638	 0.582	
Lobular	inflammation	
Total	FIS	 1.528	 0.056	 0.699	
Fibrosis	




Total	BIV2	 0.541	 0.980	 0.180	
Ballooning	
Total	BIV2	 0.947	 0.561	 0.277	
Lobular	inflammation	
Total	BIV2	 1.411	 0.098	 0.363	
Fibrosis	




Total	CLDQ		 1.834	 0.019	 0.808	
Ballooning	
Total	CLDQ		 1.160	 0.310	 0.726	
Lobular	inflammation	
Total	CLDQ	 0.849	 0.738	 0.660	
Fibrosis	

























Age	 0.960	 0.931-0.989	 0.007	
Gender	 1.511	 0.699-3.266	 0.294	
BMI	 1.065	 0.991-1.145	 0.0891	
T2DM	 1.436	 0.638-3.229	 0.382	
ALT	 1.000	 0.994-1.006	 0.988	
AST	 0.999	 0.987-1.011	 0.895	
Albumin	 1.068	 0.948-1.203	 0.281	
Platelets	 1.005	 1.000-1.010	 0.039	
Steatosis	 0.941	 0.542-1.633	 0.941	




Fibrosis	 0.983	 0.740-1.304	 0.903	
Severe	Fibrosis	 0.983	 0.451-2.142	 0.966	
Cirrhosis	 0.753	 0.235-2.411	 0.633	
NASH	 1.295	 0.599-2.799	 0.511	























































































































































































p=0.006).	LI	correlated	with	the	“physical” and “social” subcategories	(Rs=	0.290,	p=<0.0001,	












































































CLDQ	scores-	relevant	subdomains	the	“emotional” subcategory	of	the	CLDQ value (4.6) 
was	lower	than	the	normal	control	population (6.0, (p=<0.0001) and	comparable	to	the	PBC 





















































































































































































































































































































































































































































































































































































































































































	 Total	NAFLD	(n=138)	 Known	NAFLD	(n=89)	 Suspected	NAFLD	(n=49)	
Mean	Age	 60.6	+/-14.4	years	 63	+/-	11.9	years	 56.6+/-	17.7	years	
Metabolic	Parameters	
	
BMI	 34.3	+/-	9.3	 35.1+/-8.4	 32.9	+/-	10.9	
Type	2	Diabetes	 66	(47.8%)	 51	(57.3%)	 15	(30.6%)	
Hypertension	 76	(55.1%)	 54	(60.7%)	 22	(44.9%)	
Dyslipidaemia	 77	(55.8%)	 61	(68.5%)	 16	(32.7%)	























Ultrasound	 19	(38.8%)	 9	(45%)	 3	(42.9%)	 1	(33.3%)	 6	(31.8%)	
CT	scan	 3	(6.1%)	 2	(10%)	 1	(14.3%)	 0	 0	
MRI	 4	(8.2%)	 3	(15%)	 1	(14.3%)	 0	 0	
Liver	Function	tests	 48	(98%)	 20	(100%)	 6	(85.7%)	 3	(100%)	 19	(100%)	
Liver	Screen	 25	(51%)	 9	(45%)	 3	(42.9%)	 1	(33.3%)	 12	(63.2%)	
Lipid	Profile	 32	(65.3%)	 12	(60%)	 3	(42.9%)	 2	(66.7%)	 	 15	(78.9%)	
Glucose	 27	(55.1%)	 11	(55%)	 3	(42.9%)	 1	(33.3%)	 12	(63.2%)	
Fibroscan	 25	(51%)	 7	(35%)	 1	(14.3%)	 2	(66.7%)	 15	(78.9%)	
Liver	Biopsy	 6	(12.2%)	 2	(10%)	 1	(14.3%)	 0	 3	(15.8%)	
Dietician	 6	(12.2%)	 0	 0	 0	 6	(31.6%)	








































































































NASH	Cirrhosis	 6	(12.2%)	 1	(5%)	 3	(42.9%)	
	
	 2	(11%)	
NAFLD	 22	(44.9%)	 4	(20%)	 1	(14.3%)	 3	(100%)	 14	(73.5%)	
NAFLD	and	Alcohol	 12	(24.5%)	 6	(30%)	 3	(42.9%)	 	 3	(15.5%)	
Other	 9	(12%)	 	 	 	 	
						AIH	 1	(1%)	 1	(5%)	 	 	 	
						BRIC	 1	(1%)	 1	(5%)	 	 	 	
						DILI	 1	(1%)	 1	(5%)	 	 	 	
						Lymphoma	 1	(1%)	 1	(5%)	 	 	 	
						PSC	 1	(1%)	 1	(5%)	 	 	 	
						Liver	Sarcoid	 1	(1%)	 1	(5%)	 	 	 	
						Cholestatic	LFTS	 1	(1%)	 1	(5%)	 	 	 	


















Ultrasound	 19	(38.8%)	 49	(55%)	 68	(49.3%)	
CT	scan	 3	(6.1%)	 11(12.4%)	 14	(10.1%)	
MRI	 4	(8.2%)	 6	(6.7%)	 10	(7.2%)	
Liver	Function	tests	 48	(98%)	 88	(98.9%)	 136	(98.6%)	
Liver	Screen	 25	(51%)	 13	(14.6%)	 38	(27.5%)	
Lipids	 32	(65.3%)	 66	(74.2%)	 98	(71%)	
Glucose	 27	(55.1%)	 44	(49.4%)	 71	(51.4%)	
Fibroscan	 25	(51%)	 25	(28%)	 50	(36.2%)	
Liver	Biopsy	 6	(12.2%)	 3	(3.4%)	 9	(6.5%)	
Dietician	 6	(12.2%)	 13	(14.6%)	 19	(13.8%)	


















































































Age	 0.996	 0.989-1.004	 0.316	
BMI	 0.996	 0.983-1.008	 0.501	
Known	NAFLD	 1.081	 0.861-1.356	 0.503	
Suspected	NAFLD	 0.925	 0.737-1.161	 0.503	
Disease	Phenotype	
NAFLD	Cirrhosis	 0.935	 0.748-1.168	 0.553	
Advanced	dx	 0.904	 0.668-1.224	 0.515	
Mild	dx	 1.106	 0.817-1.485	 0.515	
Undetermined	dx	 0.995	 0.790-1.254	 0.967	
Patient	Metabolic	Profile	
Diabetes	 0.918	 0.719-1.174	 0.496	
Hypertension	 1.063	 0.823-1.373	 0.640	
Dyslipidaemia	 1.085	 0.832-1.414	 0.546	
Investigations	Performed	
Abdominal	USS	 1.014	 0.807-1.274	 0.904	
Fibroscan	 1.112	 0.275-4.498	 0.882	
Hospitalisation	 0.996	 0.728-1.283	 0.814	













































Mean	Age	 60.6	+/-14.4	years	 59.5	+/-	11.3	 0.564	
Type	2	Diabetes	 66	(47.8%)	 9	(11.4%)	 <0.0001	
Hypertension	 76	(55.1%)	 12	(15.2%)	 <0.0001	
Dyslipidaemia	 77	(55.8%)	 9	(11.4%)	 <0.0001	


















Ultrasound	 68	(49.3%)	 62	(78.5%)	 <0.0001	
CT	scan	 14	(10.1%)	 21	(26.6%)	 <0.0001	
MRI	 10	(7.2%)	 11	(13.9%)	 0.054	
Liver	Function	tests	 136	(98.6%)	 79	(100%)	 0.283	
Liver	Screen	 38	(27.5%)	 10	(12.7%)	 <0.0001	
Lipids	 98	(71%)	 5	(6.3%)	 <0.0001	
Glucose	 71	(51.4%)	 5	(6.3%)	 <0.0001	
Fibroscan	 50	(36.2%)	 14	(17.7%)	 0.005	
Liver	Biopsy	 9	(6.5%)	 0	 0.030	
Hospitalisation	Incidence	 33	(23.9%)	 23	(29%)	 0.418	
Average	Number	of	days	 3	+/-4	 9	+/-14	 0.006	












































































































































Procedure	 Unit	cost	 Total	NAFLD(n=138)	 Cost	(£)	 ALD(n=79)	 Cost	(£)	
Imaging	
US	 70.62	 108	 7626.96	 112	 7909.44	
CT	 305.1	 16	 4881.6	 30	 9153	
MRI	 357.62	 10	 3576.2	 11	 3933.82	
	 	 134	 16084.76	 153	 20996.26	
Non-invasive	Assessment	
Fibroscan	 136.13	 50	 6806.5	 14	 1905.82	
Bloods	
LFTS	 12.98	 315	 4088.7	 150	 1947	
Electrolyte	profile	 5.84	 315	 1839.6	 150	 876	
FBC	 5.04	 315	 1587.6	 150	 756	
COAG	 5.62	 315	 1770.3	 150	 843	
Liver	screen	 91	 38	 3458	 10	 910	
AFP	 9.91	 127	 1258.57	 133	 1318.03	
Lipid	 4.98	 229	 1140.42	 13	 64.74	
Glucose	 3.02	 174	 525.48	 12	 36.24	
	 	 1828	 15668.67	 736	 6751.01	
Procedures	
Liver	Biopsy	 157.35	 9	 1416.15	 0	 0	
OGD	 202.25	 12	 2427	 16	 3236	
	 	 21	 3843.15	 16	 3236	
Hospitalisation	
1	day	Hospital	 317.31	 91	 28875.21	 232	 73615.92	
Medical	Personnel	
Consultant	hours	 77.31	 33	 2551.23	 14	 1082.34	
Registrar	Hours	 52.62	 17	 894.54	 7	 368.34	
Dietician	 32.9	 19	 625.1	 0	 0	
Nurse		 27.9	 50	 1395	 21	 585.9	
	 	 119	 5465.87	 42	 2036.58	
Facility	Fee/Admin	
Room	charge	per	hour	 20.83	 50	 1041.5	 21	 437.43	
Secretary	to	type	letters	 15.27	 14	 213.78	 8	 122.16	
	 	 64	 1255.28	 29	 559.59	
Total	Costs	 	 	 77999.44	 	 109101.18	
Total	Costs	-	Hospitalisation	 	 	 49124.23	 	 35485.26	
Total	Annual	cost	(X12)	 	 	 935993.28	 	 1,309,214.16	













































































US	 70.62	 81	 5720.22	 99	 6991.38	
CT	 305.1	 14	 4271.4	 29	 8847.9	
MRI	 357.62	 7	 2503.34	 11	 3933.82	
		 		 102	 12494.96	 139	 19773.1	
Non-invasive	Assessment	
Fibroscan	 136.13	 10	 1361.3	 4	 544.52	
Bloods	
LFTS	 12.98	 130	 1687.4	 133	 1726.34	
Electrolyte	profile	 5.84	 130	 759.2	 133	 776.72	
FBC	 5.04	 130	 655.2	 133	 670.32	
COAG	 5.62	 130	 730.6	 133	 747.46	
Liver	screen	 91	 10	 910	 9	 819	
AFP	 9.91	 127	 1258.57	 91	 901.81	
Lipid	 4.98	 90	 448.2	 10	 49.8	
Glucose	 3.02	 64	 193.28	 11	 33.22	
		 		 811	 6642.45	 653	 5724.67	
Procedures	
Liver	Biopsy	 157.35	 3	 472.05	 0	 0	
OGD	 202.25	 12	 2427	 16	 3236	
		 		 15	 2899.05	 16	 3236	
Hospitalisation	
1	day	Hospital	 317.31	 80	 25384.8	 232	 73615.92	
Medical	Personnel	
Consultant	hours	 77.31	 11	 850.41	 11.8	 912.258	
Registrar	Hours	 52.62	 6	 315.72	 6	 315.72	
Dietician	 32.9	 6	 197.4	 0	 0	
Nurse		 27.9	 16.5	 460.35	 17.8	 496.62	
		 		 39.5	 1823.88	 35.6	 1724.598	
Facility	Fee/Admin	
Room	charge	per	hour	 20.83	 16.5	 343.695	 17.8	 370.774	
Secretary	to	type	
letters	
15.27	 5.5	 83.985	 6.6	 100.782	
		 		 22	 427.68	 24.4	 471.556	
Total	Costs	 		 		 51034.12	 1104	 105090.4	
Total	Annual	cost	
(X12)	
	 	 612,409.44	 	 1,261,084.8	
Total	Costs	-	
Hospitalisation	
		 		 25649.32	 872	 31474.44	
Annual	cost	per	
patient	
















































































Imaging	 	 	 	 	 	
US	 70.62	 86	 6073.32	 22	 1553.64	
CT	 305.1	 14	 4271.4	 2	 610.2	
MRI	 357.62	 6	 2145.72	 4	 1430.48	
	 	 106	 12490.44	 28	 3594.32	
Non-invasive	Assessment	
Fibroscan	 136.13	 25	 3403.25	 25	 3403.25	
Bloods	
LFTS	 12.98	 198	 2570.04	 117	 1518.66	
Electrolyte	profile	 5.84	 198	 1156.32	 117	 683.28	
FBC	 5.04	 198	 997.92	 117	 589.68	
COAG	 5.62	 198	 1112.76	 117	 657.54	
Liver	screen	 91	 13	 1183	 25	 2275	
AFP	 9.91	 108	 1070.28	 19	 188.29	
Lipid	 4.98	 147	 732.06	 82	 408.36	
Glucose	 3.02	 102	 308.04	 72	 217.44	
	 	 1162	 9130.42	 666	 6538.25	
Procedures	
Liver	Biopsy	 157.35	 3	 472.05	 6	 944.1	
OGD	 202.25	 9	 1820.25	 3	 606.75	
	 	 12	 2292.3	 9	 1550.85	
Hospitalisation	
1	day	Hospital	 317.31	 84	 26654.04	 7	 2221.17	
Medical	Personnel	
Consultant	hours	 77.31	 17	 1314.27	 16	 1236.96	
Registrar	Hours	 52.62	 9	 473.58	 8	 420.96	
Dietician	 32.9	 13	 427.7	 6	 197.4	
Nurse		 27.9	 26	 725.4	 24	 669.6	
	 	 65	 2940.95	 54	 2524.92	
Facility	fees/Admin	
Room	charge	per	hour	 20.83	 26	 541.58	 24	 499.92	
Secretary	to	type	letters	 15.27	 9	 137.43	 5	 76.35	
	 	 35	 679.01	 29	 576.27	
Total	Costs	 	 1489	 57590.41	 	 20409.03	
Total	Costs	-	Hospitalisation	 	 1405	 30936.37	 	 18187.86	
Total	Annual	cost	(X12)	 	 	 691084.92	 	 244908.36	
























Explanatory	variable	 Co-efficient	 Z	 p-value	
Age	 0.083	 0.920	 0.359	
BMI	 0.046	 0.534	 0.594	
Suspected	NAFLD	 -0.167	 -1.827	 0.070	
Time	to	first	OPD	 -0.137	 -1.616	 0.109	
Number	of	OPD	 0.177	 2.053	 0.042	
Patient	metabolic	profile	
Type	II	Diabetes	Mellitus	 0.107	 1.091	 0.278	
Hypertension	 0.032	 0.307	 0.759	
Dyslipidaemia	 -0.248	 -2.262	 0.026	
Histological	Stage	





















Information	on	patterns	of	utilization	of	 services	 in	hepatology	outpatient	departments	 is	
fundamental	to	inform	policy	makers	about	resource	priorities	and	potential	obstacles	in	the	
delivery	 of	 this	 service.	 Little	 published	 information	 on	OPD	 resources	 utilisation	 and	 the	
incumbent	 economic	 burden	 of	 NAFLD	 is	 available	 despite	 the	 increase	 in	 peer-reviewed	
NAFLD	publications	(365).		




















regulatory	 assessment	makes	 it	 an	 area	of	 chronic	 liver	 disease	of	 great	 interest	 in	many	
health	care	systems.	The	25%	estimate	for	the	global	prevalence	of	NAFLD	is	widely	accepted	






Most	 of	 the	 morbidity	 and	 mortality	 associated	 with	 liver	 disease	 occurs	 in	 those	 with	
advanced	fibrosis	(373).	In	this	study,	86%	of	the	ALD	cohort	and	40%	of	the	NAFLD	cohort	
had	cirrhosis.	This	 is	not	an	uncommon	demographic	 in	a	 tertiary	 facility,	as	Chronic	Liver	
Disease	(CLD)	care	guidelines	advocate	referral	for	HCC	surveillance	when	there	is	a	clinical	
suspicious	of	advanced	fibrosis/cirrhosis	(374).		
In	 this	 study,	 the	 multivariate	 analysis	 preformed	 showed	 that	 advancing	 disease	 was	
predictive	of	increased	costs	in	NAFLD.	This	is	in	keeping	with	US	studies	that	report	a	90%	




further	 perpetuated	 by	 the	 increasing	 prevalence	 of	 obesity	 observed	 in	 the	 pediatric	
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population	 (0.7%	 in	 1975	 to	 5.6%	 in	 2016	 in	 girls,	 and	 from	0.9%	 to	 7.8%	 in	 boys)	 (376).	









































































































were	higher	 (48%,	55%	and	56%)	 than	 in	 the	ALD	 cohort	 (11%,	15%	and	11%).	 	Although	
metabolic	 co-morbidity	management	was	 not	 costed	 in	 this	 study,	 previous	 studies	 have	
reported	 increasing	 costs	 with	 the	 presence	 of	 metabolic	 co-morbidities	 (obesity	 and	





(339,	 340).	 Several	 epidemiological	 studies	 support	 the	 view	 that	 there	 is	 a	 strong	 causal	
relationship	 between	 consumption	 of	 a	 diet	 high	 in	 fat	 (and/or	 presence	 of	 T2DM),	 the	
consumption	 of	 alcohol	 and	 progressive	 liver	 disease	 (335,	 336,	 338,	 390,	 391).	 Amongst	
patients	 with	 high	 alcohol	 consumption,	 obesity	 is	 an	 independent	 risk	 factor	 for	 acute	









T2DM	 in	NAFLD	was	48%,	marginally	 lower	 than	 that	observed	 in	 the	US	among	 cirrhotic	
NAFLD	patients	 (60%)	 (372).	As	expected,	 lower	 rates	of	 T2DM	were	 reported	 in	 the	ALD	
group	(11%).	In	support	of	this	observation,	there	is	epidemiological	evidence	to	suggest	that	
	 123	
consumers	 of	 moderate	 levels	 of	 alcohol	 have	 a	 lower	 risk	 of	 T2DM	 compared	 to	 non-











expenses.	 Their	 main	 use	 is	 in	 assessing	 liver	 synthetic	 function,	 particulary	 in	 advanced	
disease.	They	remain	of	limited	value	in	detecting	alcohol	excess	or	diagnosing	NAFLD	(406-
410).	AFP	costs	are	also	high	in	both	groups.	This	serological	investigation	is	of	partciular	use	























Adverse	 outcomes	 in	 NAFLD	 are	 related	 to	 histological	 subtype,	 patients	 with	 advanced	
fibrosis	 and	NASH	 in	 addition	 to	 steatosis	 are	 at	 an	 increased	 risk	 of	 liver	mortality	 (82).	




is	suspected	as	a	co-existing	chronic	 liver	disease	(121-123).	 In	this	study,	 liver	biopsy	was	
performed	in	only	9/138	patients	seen	in	hepatology	OPD	over	a	4-week	period	(projected	
estimates	 ~108	 liver	 biopsies	 for	 NAFLD	 per	 year).	 Lower	 numbers	 are	 reflective	 of	 the	











of	 comprehensive	 staging	 investigations	 to	 efficiently	 and	 appropriately	 manage	 NAFLD	
patients.		
In	contrast,	 liver	biopsy	is	seldom	performed	in	ALD.	Despite	this	current	trend,	it	 is	worth	





which	 was	 diagnosed	 by	 radiology	 thus,	 the	 presence	 of	 alcoholic	 hepatitis	 was	 not	











































































































































































characterised	 by	 the	 presence	 of	 steatosis,	 lobular	 or	 portal	 inflammation,	 hepatocyte	
ballooning	and	fibrosis	(52).	Fibrosis	is	cited	as	the	key	histological	feature	predictive	of	clinical	
outcomes	(53,	54,	56,	128).	In	simple	terms,	liver	fibrosis	represents	a	chronic	repair	process	





























Liver	 biopsy	 is	 the	 reference	 standard	 for	 fibrosis	 assessment.	 However,	 the	 increasing	
prevalence	of	NAFLD	necessitates	a	shift	 from	histology	towards	the	development	of	non-











































































































The	 objective	 of	 this	 study	 is	 to	 validate	 the	 use	 of	 proteomic	 biomarkers	 to	 predict	
histological	liver	disease	severity.		












































variables:	AST/ALT	ratio	>0.8-2	points; a BMI	≥28 – 1	point;	and	the	presence	of	diabetes – 
1	point. The	possible	score	ranges	from	0	to	4 points.	The	FIB-4	score	was	calculated:	age	× 
AST (IU/l)/platelet	count (×109/litre)	×√ALT (IU/l).	The	NAFLD	fibrosis	score	was	calculated	
according	to	the	following	formula:	−1.675+0.037×age (years)+0.094×BMI (kg/m2)	
+1.13×impaired	fasting	glycaemia or diabetes	(yes=1,	no=0)	+0.99×AST/ALT ratio 
−0.013×platelet (×109/litre)	−0.66×albumin (g/dl).	The	ADAPT	score	was	calculated:	
ADAPT=exp	(log10(Age×PROC3))	





































































	 F0	 F0	 F1	 F2	 F3	 F4	 P-Value	
Number	of	patients	 18	 26	 56	 59	 57	 31	 	
Age	(years)	 49	+/-	9	 42+/-12	 49+/-12	 51+/-14	 55+/-13	 58+/-8	 <0.001	
Gender	(male)	 9	(50%)	 20	(77%)	 35	(63%)	 35	(59%)	 30	(53%)	 12	(39%)	 0.073	
BMI	(Kg/m2)	 30+/-6	 28+/-4	 32+/-6	 33+/-6	 33+/-6	 37+/-6	 <0.001	
T2DM		 3	(17%)	 4	(15%)	 16	(29%)	 35	(59%)	 39	(68%)	 28	(90%)	 <0.001	
ALT	(U/l)	 44+/-29	 72+/-29	 69+/-49	 68+/-40	 77+/-46	 75+/-38	 <0.001	
AST	(U/l)	 30+/-12	 39+/-13	 43+/-26	 45+/-24	 56+/-24	 64+/-37	 <0.001	
Albumin	(g/dl)	 44+/-3	 45+/-4	 44+/-6	 44+/-5	 44+/-5	 42+/-5	 0.186	
Platelets	(X109/l)	 252+/-88	 255+/-62	 230+/-62	 236+/-65	 227+/-83	 197+/-108	 0.001	
Cholesterol	(mg/dl)	 5.7+/-1	 11+/-33	 5.2+/-1.5	 4.9+/-1.4	 8.5+/-26	 4.6+/-1.2	 0.058	
Triglycerides	(mg/dl)	 5.7+/-17	 2.5+/-2.3	 2.2+/-2	 2.1+/-2	 6.4+/-29	 2.3+/-1.3	 0.312	
Collagen	PROC3(ng/ml)	 9.6+/-3	 14.2+/-6	 12.7+/-6	 17+/-11	 26.5+/-18	 31.5+/-18.4	 <0.001	
Collagen	PROC6(ng/ml)	 7.2+/-2	 8.3+/-2	 8.4+/-3	 9+/-3	 12.5+/-7	 13.1+/-5	 <0.001	
PROC4	(ng/ml)	 217+/-90	 238+/-115	 264+/-116	 302+/-141	 317+/-159	 385+/-152	 <0.001	
C4M	(ng/ml)	 26+/-9	 24+/-8	 27+/-9	 28+/-11	 29+/-10	 31+/-10	 0.025	
C3M	(ng/ml)	 10+/-4	 11+/-4	 11+/-3	 12+/-4	 12+/-5	 13+/-4	 0.105	
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LOXL2	(ng/ml)	 54+/-33	 48+/-45	 50+/-49	 55+/-42	 58+/-42	 53+/-37	 0.809	
FPA	(ng/ml)	 4987+/-2600	 3492+/-1525	 4848+/-2104	 4940+/-2333	 4152+/-2090	 3912+/-1714	 0.013	
VWF	(ng/ml)	 12+/-8	 11+/-7	 11+/-6	 13+/-11	 20+/-32	 14+/-7	 0.498	
Fibrosis	Stage	(0/1/2/3/4)	 18/0/0/0/0	 26/0/0/0/0	 0/56/0/0/0	 0/0/59/0/0	 0/0/0/57/0	 0/0/0/0/31	 <0.001	
Steatosis	0/1/2/3	 0/16/2/0	 0/2/12/12	 0/23/23/10	 0/19/23/17	 2/10/21/24	 0/13/14/4	 <0.001	
Ballooning	0/1/2	 16/2/0	 16/5/5	 14/29/13	 11/30/18	 3/22/32	 2/15/14	 <0.001	
Lobular	Inflammation	
0/1/2/3	
10/8/0/0	 3/16/7/0	 4/36/16/0	 3/27/26/3	 0/14/32/11	 0/3/12/16	 <0.001	
NAS	 2+/-0.5	 4+/-1	 4+/-1	 4+/-2	 6+/-2	 5+/-1	 <0.001	
FIB4	 1.04+/-0.54	 0.89+/-0.62	 1.29+/-0.83	 1.40+/-0.86	 1.84+/-1.14	 2.68+/-1.43	 <0.001	
AAR	 0.4+/-0.21	 0.60+/-0.26	 0.73+/-0.33	 0.71+/-0.21	 0.93+/-0.30	 0.93+/-0.37	 <0.001	
NAFLD	Fibrosis	Score	 -2.23+/-1.14	 -3.053+/-1.296	 -1.676+/-1.485	 -1.321+/-1.521	 -0.836+/-1.784	 0.579+/-1.987	 <0.001	
APRI	 0.40+/-0.21	 0.50+/-0.3	 0.61+/-0.5	 0.61+/-0.39	 0.80+/-0.41	 1.10+/-0.58	 <0.001	
ADAPT	Score	 5+/-0.9	 4.8+/-1.2	 5.2+/-1.1	 6.2+/-1.7	 7.65+/-2.1	 9.0+/-2.2	 <0.001	
BARD	Score	 2+/-1	 1+/-1	 2+/-1	 2+/-1	 2+/-	1	 3+/-1	 <0.001	









	 F0	 F0	 F1	 F2	 F3	 F4	 P-Value	
Number	of	patients	 14	 10	 19	 23	 29	 19	 	
Age	(years)	 54	+/-	10	 47+/-14	 43+/-12	 47+/-14	 58+/-10	 58+/-9	 <0.001	
Gender	(male)	 11	(79%)	 7	(70%)	 11	(58%)	 13	(57%)	 20	(69%)	 9	(47%)	 0.458	
BMI	(Kg/m2)	 29+/-5	 29+/-6	 30+/-6	 31+/-5	 36+/-8	 35+/-5	 <0.001	
T2DM		 3	(21%)	 3	(30%)	 6	(32%)	 7	(30%)	 19	(66%)	 17	(90%)	 <0.001	
ALT	(U/l)	 57+/-39	 56+/-30	 76+/-39	 70+/-41	 66+/-35	 67+/-45	 0.392	
AST	(U/l)	 33+/-16	 34+/-13	 53+/-27	 44+/-27	 52+/-25	 49+/-35	 0.002	
Albumin	(g/dl)	 44+/-5	 45+/-4	 44+/-4	 46+/-3	 44+/-3	 42+/-4	 0.057	
Platelets	(X109/l)	 238+/-63	 221+/-57	 258+/-66	 243+/-53	 205+/-57	 182+/-52	 0.002	
Cholesterol	(mg/dl)	 14+/-32	 5+/-1	 5.5+/-1.6	 5.6+/-2	 4.7+/-1.1	 5+/-1.1	 0.369	
Triglycerides	(mg/dl)	 1.5+/-0.5	 1.9+/-2.2	 2.8	+/-4.7	 2.7+/-1.7	 9.6+/-37.4	 2.0+/-0.7	 0.032	
Collagen	PROC3(ng/ml)	 11.6+/-5.2	 10.9+/-4.6	 17.8+/-15.7	 14.6+/-4.3	 25.6+/-17.2	 24.5+/-15.8	 <0.001	
Collagen	PROC6(ng/ml)	 9.6+/-6.4	 7.3+/-2.2	 8.1+/-2.9	 10.2+/-4	 10.4+/-2.9	 10.9+/-3.7	 0.006	
PROC4	(ng/ml)	 255+/-137	 208+/-65	 224+/-86	 303+/-143	 297+/-96	 356+/-234	 0.041	
C4M	(ng/ml)	 25+/-8	 22+/-7	 25+/-7	 28+/-8.4	 29+/-11	 30+/-15	 0.260	
C3M	(ng/ml)	 12+/-6	 10+/-3	 6.8+/-2.8	 12.6+/-4	 11.7+/-3.4	 12.5+/7.6-	 0.235	
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LOXL2	(ng/ml)	 44+/-30	 59+/-47	 13+/-5.2	 86+/-95	 45+/-29	 60+/-55	 0.353	
FPA	(ng/ml)	 4030+/-1776	 3935+/-1182	 4799+/-1737	 4525+/-2199	 4361+/-2009	 4839+/-1695	 0.701	
VWF	(ng/ml)	 7.7+/-3.3	 10.1+/-6	 10.8+/-4.11	 13.9+/-7.4	 17.9+/-5.6	 21+/-15.7	 <0.001	
Fibrosis	Stage	
(0/1/2/3/4)	
14/0/0/0/0	 10/0/0/0/0	 0/19/0/0/0	 0/0/23/0/0	 0/0/0/29/0	 0/0/0/0/19	 <0.001	
Steatosis	0/1/2/3	 1/12/1/0	 0/3/3/4	 1/5/8/5	 0/4/9/10	 0/7/14/8	 0/6/9/4	 0.007	
Ballooning	0/1/2	 13/1/0	 6/1/3	 3/11/5	 2/17/4	 1/12/16	 1/6/6	 <0.001	
Lobular	Inflammation	
0/1/2/3	
6/8/0/0	 2/6/2/0	 0/16/2/1	 0/15/8	 1/8/17/3	 1/8/8/2	 <0.001	
NAS	 2+/-0.5	 4+/-0.4	 4+/-2	 5+/-1	 5+/-1	 5+/-2	 <0.001	
FIB4	 1.10+/-0.54	 1.12+/-0.60	 1.21+/-0.89	 1.15+/-0.65	 2.09+/-1.39	 2.51+/-1.19	 <0.001	
AAR	 0.65+/-0.19	 0.74+/-0.44	 0.82+/-0.53	 0.74+/-0.35	 0.85+/-0.25	 0.99+/-0.31	 0.007	
NAFLD	Fibrosis	Score	 -2.128+/-1.530	 -1.955+/-0.968	 0.647+/-0.371	 -2.15+/-1.68	 -0.13+/-1.14	 0.610+/-1.2981	 <0.001	
APRI	 0.42+/-0.18	 0.47+/-0.18	 0.65+/-0.37	 0.67+/-0.43	 0.87+/-0.75	 0.1+/-0.54	 <0.001	
ADAPT	Score	 5.2+/-1.3	 4.8+/-1.3	 5.3+/-2	 5.4+/-1.1	 7.9+/-2.3	 8.1+/-2.3	 <0.001	
BARD	Score	 1+/-1	 1+/-1	 2+/-1	 2+/-1	 3+/-1	 3+/-1	 <0.001	

































































































































































































N=361	 PROC3	 P-value	 PROC4	 P-
value	




Steatosis	 0.261	 <0.0001	 0.101	 0.055	 0.018	 0.743	 0.088	 0.095	 0.092	 0.081	
Hepatocyte	
Ballooning	
0.228	 <0.0001	 0.020	 0.710	 0.170	 0.001	 -0.20	 0.702	 0.040	 0.452	
Lobular	
Inflammation	
0.338	 <0.0001	 0.082	 0.119	 0.097	 <0.0001	 0.07	 0.182	 0.093	 0.077	
NAS	Score	 0.388	 <0.0001	 0.094	 0.077	 0.169	 0.002	 0.058	 0.277	 0.101	 0.058	
*Statistical	test;	Spearmann	Rank	Correlation	Co-efficient	(Rs)	
Table	4.6.	Association	of	mean	serum	collagen	fragment	levels	and	steatohepatitis		
N=361	 PROC3	 PROC4	 PROC6	 C3M	 C4M		
Steatosis	 <0.0001	 0.189	 0.688	 0.146	 0.354	
Hepatocyte	Ballooning	 <0.0001	 0.180	 0.003	 0.596	 0.655	
Lobular	Inflammation	 <0.0001	 0.379	 0.002	 0.529	 0.356	





























PROC3	 1.100	 1.07-1.134	 <0.0001	 1.067	 1.029-
1.107	
<0.0001	
PROC4	 1.003	 1.00-1.005	 0.001	 	 	 	
PROC6	 1.279	 1.17-1.399	 <0.0001	 1.141	 1.028-
1.265	
0.013	
C3M	 1.046	 0.98-1.11	 0.157	 	 	 	
C4M	 1.027	 1.0-1.055	 0.048	 0.906	 0.835-
0.982	
0.016	
Age	 1.047	 1.02-1.072	 <0.0001	 1.040	 1.008-
1.073	
0.015	
Gender	 1.807	 1.07-3.061	 0.028	 	 	 	
BMI	 1.081	 1.04-1.130	 <0.0001	 	 	 	
T2DM	 5.556	 3.09-9.992	 <0.0001	 3.036	 1.451-
6.352	
0.003	
ALT	 1.005	 0.10-1.011	 0.095	 	 	 	
AST	 1.030	 1.02-1.043	 <0.0001	 1.020	 1.005-
1.035	
0.007	
Albumin	 0.969	 0.92-1.018	 0.212	 	 	 	
Platelets	 0.996	 0.99-1.000	 0.033	 	 	 	
Cholesterol	 1.003	 0.98-1.019	 0.673	 	 	 	












	 PROC3	 PROC6	 PROC3+PROC6	 C4M	
AUROC	 0.78	 0.75	 0.79	 0.59	
Optimal	Cut	off		 >17.5ng/ml	 >10.5ng/ml	 >34.1ng/ml	 >27.7ng/ml	
Sensitivity	 68%	 62%	 59%	 57%	
Specificity	 77%	 83%	 89%	 63%	
PPV	 63%	 67%	 76%	 46%	
NPV	 81%	 80%	 80%	 72%	


















PROC3, A = 0.78
PROC6, A = 0.75
PROC3PROC6, A = 0.79






	 PROC3	 PROC6	 PROC3+PROC6	 C4M	
AUROC	 	 	 	 	
F0	 0.69	 0.68	 0.71	 0.63	
F1	 0.68	 0.64	 0.68	 0.53	
F2	 0.47	 0.46	 0.47	 0.52	
F3	 0.70	 0.68	 0.71	 0.54	



































0.788	 	 	 	
PROC6	 1.018	 0.957-
1.083	
0.568	 	 	 	
C3M	 1.010	 0.943-
1.081	
0.785	 	 	 	
C4M	 1.009	 0.979-
1.040	
0.545	 	 	 	
Age	 0.993	 0.972-
1.015	
0.523	 	 	 	
Gender	 0.722	 0.415-
1.257	
0.250	 	 	 	
BMI	 1.030	 0.983-
1.079	













<0.0001	 	 	 	
Albumin	 1.050	 0.996-
1.107	
0.071	 	 	 	
Platelets	 1.000	 0.997-
1.004	





N=247	 PROC3	 PROC4	 PROC6	 C3M	 C4M	
AUROC	 0.69	 0.53	 0.56	 0.54	 0.54	
P-Value		 <	0.0001	 0.46	 0.14	 0.31	 0.31	
Cut	-off	 >16.5ng/ml	 >270ng/ml	 >7.5ng/ml	 >9.1ng/ml	 >20.35ng/ml	
Sensitivity	 54%	 48%	 73%	 73%	 80%	
Specificity	 78%	 63%	 38%	 38%	 32%	
PPV	 85%	 75%	 75%	 73%	 74%	
NPV	 42%	 34%	 36%	 37%	 40%	












N=114	 PROC3	 PROC6	 PROC3+PROC6	 C4M	




>17.5ng/ml	 >10.5ng/ml	 >34.1ng/ml	 >27.7ng/ml	
Sensitivity	 58%	 49%	 38%	 46%	
Specificity	 80%	 77%	 86%	 70%	
PPV	 68%	 61%	 67%	 52%	
NPV	 73%	 67%	 65%	 64%	






































N=114	 PROC3	 PROC4	 PROC6	 C3M	 C4M	
AUROC	 0.63	 0.54	 0.57	 0.49	 0.55	
P-Value		 0.03	 0.48	 0.29	 0.92	 0.43	
Cut	-off	 >16.5ng/ml	 >270ng/ml	 >7.5ng/ml	 >9.1ng/ml	 >20.35ng/ml	
Sensitivity	 46	 45	 74	 63	 75	
Specificity	 71	 65	 42	 39	 35	
PPV	 80	 77	 76	 72	 75	
NPV	 34	 31	 39	 29	 35	



























N=346	 AAR	 APRI	 BARD	 NFS	 FIB4	 PROC3	 PROC4	 PROC6	 C3M	 C4M	
AUROC	 0.68	 0.75	 0.73	 0.80	 0.78	 0.76	 0.63	 0.73	 0.55	 0.59	
Cut	-off	 >0.8	 >1.5	 >2	 >0.676	 >2.67	 >17.5ng/ml	 >266ng/ml	 >10.5ng/ml	 >7.7ng/ml	 >22.7ng/ml	
Sensitivity	 54%	 11%	 82%	 31%	 22%	 66%	 61%	 57%	 83%	 53%	
Specificity	 68%	 96%	 51%	 95%	 94%	 77%	 64%	 81%	 16%	 66%	
PPV	 51%	 63%	 50%	 79%	 71%	 64%	 51%	 64%	 38%	 48%	
NPV	 71%	 64%	 83%	 69%	 67%	 79%	 73%	 76%	 61%	 69%	






















Age	(years)	 50+/-13	 50+/-13	 51	+/-	12	 0.665	
Gender	(male)	 88	(60%)	 63	(58%)	 25	(64%)	 0.491	
BMI	(Kg/m2)	 32+/-6	 32+/-6	 32+/-6	 0.318	
T2DM		 69	(47%)	 51	(47%)	 18	(46%)	 0.946	
ALT	(U/l)	 72+/-46	 73+/-47	 68+/-43	 0.461	
AST	(U/l)	 50+/-31	 48+/-29	 54+/-37	 0.910	
Albumin	(g/dl)	 43+/-5	 43+/-6	 43+/-4	 0.993	
Platelets	
(X109/l)	
235+/-72	 239+/-76	 224+/-60	 0.225	
Cholesterol	
(mg/dl)	
8.3+/-23	 8.3+/-24	 8.0+/-19	 0.410	
Triglycerides	
(mg/dl)	
5.5+/-25	 4.8+/-22	 7.5+/-33	 0.432	
Collagen	PRO-
C3(ng/ml)	
20+/-15	 20+/-16	 21+/-14	 0.592	
Collagen	PRO-
C6(ng/ml)	
10+/-5	 10+/-5	 10+/-4	 0.606	
PRO-C4	
(ng/ml)	
275+/-124	 276+/-129	 272+/-110	 0.901	
C4M	(ng/ml)	 27+/-10	 27+/-10	 27+/-11	 0.908	
C3M	(ng/ml)	 12+/-4	 12+/-4	 12+/-5	 0.870	
LOXL2	ng/ml	 53+/-44	 54+/-42	 52+/-50	 0.601	
FPA	ng/ml	 3982+/-1880	 4015+/-1973	 3889+/-1612	 0.130	








1/56/45/46	 0/39/35/35	 1/17/10/11	 0.285	
Ballooning	
0/1/2	






























































































LOXL2	 1.001	 0.993-1.009	 0.834	 	 	 	
FPA	 1.000	 1.000-1.000	 0.771	 	 	 	
VWF	 1.050	 1.005-1.097	 0.028	 1.056	 1.003-
1.111	
0.039	
Age	 1.057	 1.024-1.091	 0.001	 1.044	 1.006-
1.083	
0.021	
Gender	 2	 0.986-4.055	 0.055	 	 	 	






ALT	 1.005	 0.998-1.013	 0.152	 	 	 	
AST	 1.018	 1.006-1.030	 0.004	 1.014	 1.002-
1.027	
0.026	
Albumin	 0.978	 0.917-1.044	 0.503	 	 	 	
Platelets	 0.995	 0.989-1.001	 0.083	 	 	 	
Cholesterol	 1.001	 0.987-1.016	 0.849	 	 	 	










N=109	 PROC3	 PROC6	 VWF	 C4M	




>17.5ng/ml	 >10.5ng/ml	 >14.5ng/ml	 >27.7ng/ml	
Sensitivity	 69%	 66%	 50%	 38%	
Specificity	 70%	 79%	 74%	 62%	
PPV	 49%	 57%	 44%	 29%	
NPV	 84%	 85%	 78%	 71%	


























Variable	 Odds	Ratio	 95%	CI	 p-value	
LOXL2	 1.005	 0.995-1.016	 0.321	
FPA	 1.000	 1-1	 0.219	
VWF	 1.003	 0.980-1.027	 0.775	
Age	 0.983	 0.951-1.016	 0.303	
Gender	 0.708	 0.311-1.615	 0.412	
BMI	 0.990	 0.923-1.062	 0.780	
T2DM	 2.167	 0.923-5.089	 0.076	
ALT	 1.034	 1.016-1.052	 <0.0001	
AST	 1.076	 1.035-1.118	 <0.0001	
Albumin	 1.052	 0.976-1.133	 0.184	









N=39	 PROC3	 PROC6	 C4M	 VWF	
AUROC	 0.85	 0.69	 0.52	 0.75	
Optimal	Cut	off		 >17.5ng/ml	 >10.5ng/ml	 >27.7ng/ml	 >14.5ng/ml	
Sensitivity	 79%	 43%	 36%	 29%	
Specificity	 80%	 68%	 68%	 84%	
PPV	 69%	 43%	 38%	 50%	
NPV	 87%	 68%	 65%	 68%	






patients	develop	 fibrosis	stage	≥F3	 (128)	alongside	NASH,	an	 injurious	process	believed	to	




















































































































Collagen	 binding,	 activation	 of	 platelets,	 fibrin	 clot	 formation	 and	 dissolution	 provide	 a	
framework	for	the	tissue	remodelling	typical	of	fibrosis	(493,	494).	However,	VWF	and	FPA	
associated	 with	 the	 collagen	 platelet	 axis	 in	 tissue	 remodelling	 did	 not	 show	 promise	 as	
biomarkers.	 There	 is	 literature	 to	 suggest	 that	 pro-thrombotic	 factor	 production	 may	 be	
driven	by	chronic	inflammation	associated	with	the	metabolic	syndrome	(MetS)	rather	than	
by	NASH	associated	necro-inflammation	(495)	LOXL2	is	responsible	for	collagen	crosslinking	
and	stability.	Despite	evidence	that	 it	 is	upregulated	 in	 fibrosis	and	tightly	correlated	with	
fibrosis	 stage	 (466,	 496),	 this	 study	 failed	 to	 show	 significant	 correlation	 with	 advanced	
fibrosis	or	steatohepatitis.	The	non-collagen	based	biomarkers	investigated	in	this	study	did	
not	 show	any	predictive	power	 in	 this	 study	 cohort.	A	possible	explanation	might	be	 that	





































































































The	Non-alcoholic	 fatty	 liver	disease	 (NAFLD)	 spectrum	 includes	 simple	 steatosis	 affecting	
>5%	of	hepatocytes	 (NAFL)	and	non-alcoholic	steatohepatitis	 (NASH),	characterised	by	the	
presence	of	steatosis,	lobular	or	portal	inflammation,	hepatocyte	ballooning	and	fibrosis	(52).	
Hepatocyte	 inflammation/ballooning	 and	 death	 are	 markers	 of	 disease	 activity	
(steatohepatitis),	which	drive	the	disease	toward	cirrhosis	and	are	quantified	by	NAS	score	
(45).	Fibrosis	is	quantified	using	the	5	point	scale	developed	by	Brunt	et	al	(48)	which	provides	
a	numerical	value	 (0-5)	 to	 indicate	how	far	 the	disease	has	progressed	on	the	pathway	to	
cirrhosis.	 	 Satisfying	 the	 Food	 and	 Drug	 Agency	 (FDA)	 definition	 of	 “clinically	 meaningful	
benefit” in NAFLD	patients at	increased	risk	of	disease	progression	involves	reducing	disease	
activity	 in	 the	 short	 term,	 and	 preventing	 progression	 to	 cirrhosis	 and	 thus	 adverse	 liver	







Liver	histology	 in	NAFLD	provides	 the	basis	 for	disease	definition	and	both	steatohepatitis	
(SH)	and	fibrosis	stage	have	been	linked	to	clinical	outcomes.	Fibrosis	is	the	only	histological	
feature	 that	 has	 been	 found	 to	 be	 independently	 associated	 with	 long-term	 prognosis.	
Advanced	fibrosis	stage	confers	an	increased	risk	of	progression	to	cirrhosis,	liver	failure	and	





Blood-based	 non-invasive	 tests	 for	 fibrosis	 can	 be	 dichotomized	 into	 “indirect	 markers”, 
including	 simple	non-invasive	 fibrosis	 scores	derived	 from	clinical	 and	biochemical	 indices	




“direct	 biomarkers” that	measure	 collagen	 deposition	 or	matrix	 turnover (177,	 508).	 The	
majority	of	non-invasive	tests	exhibit	high	negative	predictive	value,	implying	that	they	are	
best	employed	to	exclude	patients	without	advanced	fibrosis	(Kleiner	<F2). However, many	
issues	 exist	 with	 currently	 available	 biomarkers.	 As	 described	 in	 chapter	 1,	 FIB4	 and	 NFS	
provide	 “indeterminate”	 results	 in	 a	 quarter	 of	 patients	 (115)	 and	 although	 elastography	
based	 techniques	 such	 as	 Fibroscan™ (vibration	 controlled	 transient	 elastography,	 VCTE) 
have	 a	 competitive	 diagnostic	 accuracy,	 they	 require	 specialist	 equipment,	 are	 operator	












































































• Assess	 the	 performance	 of	 PROC3	 as	 a	 NASH-fibrosis	 biomarker	within	 the	 BEST	
diagnostic	context	of	use	
• Develop	and	validate	a	novel	biomarker	panel	incorporating	PROC3	and	determine	its	
performance	 in	 comparison	 to	 established	 clinical	 scores	 and	 previously	 reported	
biomarker	panels	



























4).	 The	 combined	 cohort	of	 449	patients	was	 randomly	 separated	 into	approximately	1/3	
(n=151)	(Discovery	cohort)	and	2/3	(n=298)	of	patients	(Validation	cohort)	for	model	building	
and	validation	 (FIBC3	and	ABC3D).	A	 cohort	of	 358	patients	was	 randomly	 separated	 into	





backward	 stepwise	 multiple	 logistic	 regression	 analysis	 to	 identify	 independent	 factors	
associated	 with	 fibrosis.	 Variables	 with	 P	 <	 0.05	 by	 multivariate	 analysis	 were	 used	 to	
construct	 scoring	systems	 (FIBC3,	ABC3D	and	PROC3PNPLA3)	 to	predict	advanced	 fibrosis.	












under	 the	 receiver	 operating	 characteristic	 (ROC)	 curve	 (the	 c-statistic)	 and	 its	 95%	
confidence	intervals.	The	5-point	fibrosis	scales	presented	both	spectrum	effect	and	ordinal	
scale	 issues.	To	overcome	 this,	we	calculated	 the	Obuchowski	measure	using	 the	package	
“nonbinROC” version	 1.0.1	 (https://CRAN.R-project.org/package=nonbinROC)	 using	 the	 R	
statistical	 analysis	 software	 platform	 (527).	 This	 is	 a	 measure	 of	 the	 probability	 that	 our	
fibrosis	index	will	correctly	rank	2	randomly	chosen	patient	samples	from	different	fibrosis	
stages	 according	 to	 the	weighting	 scheme,	with	 a	penalty	 score	of	 1	 for	 incorrect	 scoring	
(528).	 The	method	of	DeLong,	DeLong	 and	Clarke-Pearson	was	 used	 to	 compare	AUROCs	



































































Age	(years)	 52+/-13	 51.6+/-13	 51.5+/-13	 0.957	
Gender	(male)	 263	(59%)	 94	(62%)	 169	(57%)	 0.260	 	
BMI	(Kg/m2)	 32.6+/-6.8	 32.9+/-7.1	 32.4+/-6.4	 0.608	
T2DM		 216	(48%)	 74	(49%)	 142	(48%)	 0.786	
ALT	(U/l)	 69+/-41	 66+/-39	 71+/-42	 0.166	
High	ALT	(>40U/l)	 340	(76%)	 112	(74%)	 228	(77%)	 0.585	
AST	(U/l)	 47+/-26	 47+/-26	 48+/-26	 0.339	
Albumin	(g/dl)	 44+/-5	 44+/-4	 44+/-5	 0.780	
Platelets	(X109/l)	 230+/-72	 225+/-61	 233+/-77	 0.448	
Cholesterol	
(mg/dl)	
7+/-14	 7+/-10	 7.1+/-16	 0.630	
Triglycerides	
(mg/dl)	
3.8+/-17	 3.6+/-16	 3.9+/-18	 0.758	
Collagen	
PROC3(ng/ml)	
18.9+/-15	 18.1+/-14	 19.3+/-15	 0.438	
Collagen	
PROC6(ng/ml)	
9.6+/-4.4	 9.3+/-4	 9.8+/-4.7	 0.501	
PROC4	(ng/ml)	 266+/-142	 253+/-147	 273+/-139	 0.067	
C4M	(ng/ml)	 27.3+/-10	 26.8+/-10.1	 27.6+/-9.8	 0.374	








10/149/171/110	 6/50/56/35	 4/99/115/75	 0.342	
Ballooning	
0/1/2	




48/219/147/24	 18/78/43/8	 30/141/104/16	 0.578	
NAS	 4+/-2	 4+/-2	 4+/-2	 0.848	









Across	 all	 histological	 features	 (steatosis,	 lobular	 inflammation,	 hepatocyte	 ballooning,	
fibrosis),	PROC3	was	positively	associated	with	increasing	NAFLD	severity	(Figure	5.3).	In	the	
discovery	cohort	(n=151),	PROC3	correlated	with	NAS	score	(Rs=0.304,	p<0.0001)	and	fibrosis	
stage	 (Rs=0.422,	 p<0.0001).	 Confirming	 that	 PROC3	 is	 primarily	 a	 fibrosis	 marker,	 the	
correlation	with	 fibrosis	 stage	 remained	 significant	when	controlling	 for	NAS	however	 the	
converse	did	not	hold	true.	Indeed,	PROC3	exhibited	the	strongest	correlation	with	fibrosis	
AAR	 0.76+/-0.31	 0.79+/-0.34	 0.75+/-0.30	 0.428	
NAFLD	Fibrosis	
Score	
-1.304+/-1.796	 -1.182+/-1.797	 -1.367+/-1.795	 0.303	
APRI	 0.68+/-0.48	 0.68+/-0.51	 0.68+/-0.46	 0.718	
ADAPT	Score	 6.3+/-2.2	 6.3+/-2.3	 6.4+/-2.2	 0.652	





254	(57%)	 	79	(52%)	 175	(59%)	 0.622	











Study	Site	 N	 %	 N	 %	 N	 %	
USP	 14	 3	 2	 1	 12	 4	
UP	 90	 21	 30	 20	 60	 21	
UNITO	 95	 21	 34	 23	 61	 20	
UNEW	 160	 35	 49	 32	 111	 37	
UM	 54	 12	 17	 11	 37	 12	










fibrosis	 was	 determined.	 PROC3	 >15.5ng/ml	 had	 an	 AUROC	 of	 0.73	 for	 the	 detection	 of	
advanced	fibrosis	>F3 (sensitivity	60%,	specificity	74%,	accuracy	68%). This was	replicated	in	
the	validation	cohort	(n=298)	(AUROC	=	0.78,	sensitivity	72%,	specificity	71%,	accuracy	71%)	














	 PPV	 NPV	 Sensitivity	 Specificity	 Accuracy	
Discovery	Cohort	(n=151)	 60	 74	 60	 74	 68	
Validation	Cohort	(n=298)	 58	 82	 72	 71	 71	
FIBC3	Validation	Cohort	
(n=298)	
63	 84	 75	 75	 75	
Optimal	PROC3	cut	off	for	detection	of	*tdNASH	with	≥F2	fibrosis:	PROC3>14.5ng/ml	
AUROC	0.68	(0.591-0.761)	
	 PPV	 NPV	 Sensitivity	 Specificity	 Accuracy	
Discovery	Cohort	(n=151)	 63	 65	 59	 69	 64	
Validation	Cohort	(n=298)	 64	 74	 70	 68	 69	
FIBC3	Validation	Cohort	
(n=298)	
63	 84	 75	 75	 75	
Optimal	PROC3	cut	off	for	detection	of	*tdNASH	with	F4	cirrhosis:	PROC3>16.5ng/ml	
AUROC	0.68	(0.535-0.817)	
	 PPV	 NPV	 Sensitivity	 Specificity	 Accuracy	
Discovery	Cohort	(n=151)	 24	 95	 74	 67	 68	
Validation	Cohort	(n=298)	 20	 95	 76	 61	 63	
FIBC3	Validation	Cohort	
(n=298)	











 TP	 TN	 FP	 FN	 	 PPV	 NPV	 SEN	 SPEC	 ACCURACY	 Actual	No.Cases	 TP(%)	
PROC3>5		
tdNASHF1234	 282	 0	 163	 4	 449	 63	 0	 99	 0	 63	 286	 99	
tdNASHF0	 15	 3	 430	 1	 449	 3	 75	 94	 1	 4	 16	 94	
tdNASHF1	 59	 2	 386	 2	 449	 13	 50	 97	 1	 14	 61	 97	
tdNASHF2	 68	 3	 377	 1	 449	 15	 75	 99	 1	 16	 69	 99	
tdNASHF3	 87	 4	 358	 0	 449	 20	 100	 100	 1	 20	 87	 100	
tdNASHF4	 53	 4	 392	 0	 449	 12	 100	 100	 1	 13	 53	 100	
Advanced	Fibrosis	 167	 4	 278	 0	 449	 38	 100	 100	 1	 38	 167	 100	
PROC3>10		
tdNASHF1234	 235	 65	 98	 51	 449	 71	 56	 82	 40	 67	 286	 82	
tdNASHF0	 11	 111	 322	 5	 449	 3	 96	 69	 26	 27	 16	 69	
tdNASHF1	 38	 93	 295	 23	 449	 11	 80	 62	 24	 29	 61	 62	
tdNASHF2	 56	 103	 277	 13	 449	 17	 89	 81	 27	 35	 69	 81	
tdNASHF3	 82	 111	 251	 5	 449	 25	 96	 94	 31	 43	 87	 94	
tdNASHF4	 48	 111	 285	 5	 449	 14	 96	 91	 28	 35	 53	 91	
Advanced	Fibrosis	 151	 100	 182	 16	 449	 45	 86	 90	 35	 56	 167	 90	
PROC3>15	
tdNASHF1234	 152	 115	 48	 134	 449	 76	 46	 53	 71	 59	 286	 53	
tdNASHF0	 4	 237	 196	 12	 449	 2	 95	 25	 55	 54	 16	 25	
tdNASHF1	 15	 203	 185	 46	 449	 8	 82	 25	 52	 49	 61	 25	
tdNASHF2	 36	 216	 164	 33	 449	 18	 87	 52	 57	 56	 69	 52	
tdNASHF3	 57	 219	 143	 30	 449	 29	 88	 66	 60	 61	 87	 66	
tdNASHF4	 40	 236	 160	 13	 449	 20	 95	 75	 60	 61	 53	 75	
Advanced	Fibrosis	 115	 197	 85	 52	 449	 58	 79	 69	 70	 69	 167	 69	
PROC3>20	
tdNASHF1234	 106	 140	 23	 180	 449	 82	 44	 37	 86	 55	 286	 37	
tdNASHF0	 1	 305	 128	 15	 449	 1	 95	 6	 70	 68	 16	 6	
tdNASHF1	 9	 268	 120	 52	 449	 7	 84	 15	 69	 62	 61	 15	
tdNASHF2	 21	 272	 108	 48	 449	 16	 85	 30	 72	 65	 69	 30	
tdNASHF3	 44	 277	 85	 43	 449	 34	 87	 51	 77	 71	 87	 51	
tdNASHF4	 31	 298	 98	 22	 449	 24	 93	 58	 75	 73	 53	 58	
Advanced	Fibrosis	 88	 241	 41	 79	 449	 68	 75	 53	 85	 73	 167	 53	
PROC3>25		
tdNASHF1234	 15	 208	 148	 78	 449	 9	 73	 16	 58	 50	 286	 5	
tdNASHF0	 1	 341	 92	 15	 449	 1	 96	 6	 79	 76	 16	 6	
tdNASHF1	 5	 300	 88	 56	 449	 5	 84	 8	 77	 68	 61	 8	
tdNASHF2	 11	 298	 82	 58	 449	 12	 84	 16	 78	 69	 69	 16	
tdNASHF3	 35	 304	 58	 52	 449	 38	 85	 40	 84	 76	 87	 40	
tdNASHF4	 26	 329	 67	 27	 449	 28	 92	 49	 83	 79	 53	 49	
Advanced	Fibrosis	 71	 260	 22	 96	 449	 76	 73	 43	 92	 74	 167	 43	









were	 conducted.	 Table	 5.5	 shows	 the	 results	 of	 univariate	 and	 multivariate	 analyses	
preformed	 in	 the	 discovery	 cohort.	 Using	 backward	 logistic	 regression,	 five	 variables	
remained	 significantly	 associated	 with	 advanced	 fibrosis:	 age,	 BMI,	 T2DM,	 platelets	 and	
PROC3.	No	multi-collinearity	was	identified	between	variables	used	in	the	model.	Variables	
were	assessed	for	all	two-way	interactions	with	no	significant	outcomes	(p>0.05).	These	five	


































































0.611	 	 	 	
AST	 1.020	 1.005-
1.034	
0.007	 	 	 	
Albumin	 0.934	 0.853-
1.021	








0.038	 	 	 	
Triglycerides	 1.024	 0.952-
1.101	






















in	a	validation	cohort	 (n=298)	and	also	 in	the	overall	combined	cohort	 (n=449).	Diagnostic	
accuracy	was	assessed	by	the	standard	AUROC	and	also	the	weighted	AUROC	computed	using	
the	Obuchowski	measure	 to	account	 for	 spectrum	effect	and	ordinal	 scale.	For	FIBC3,	 the	
AUROC	 remained	 high	 in	 both	 the	 validation	 cohort	 (0.83,	 95%CI	 0.777-0.880)	 and	 the	
combined	cohort	(0.85,	95%CI	0.812-0.886).	The	weighted	AUROC	was	calculated	to	be	0.77,	
0.75	and	0.79	in	the	combined,	discovery	and	validation	cohorts	respectively.	Similar	results	
were	 obtained	 for	 ABC3D	 with	 AUROC	 of	 0.81	 and	 0.83	 in	 the	 validation	 and	 combined	
cohorts	 respectively	 (Table	 5.6).	 Reduced	 bias	 estimates	 of	 predicted	 probability	 were	
calculated	in	the	discovery	and	validation	cohorts,	employing	the	leave-one-out	method	of	


















SD	 95%	CI	 AUROC	 95%	CI	 Adj	
AUROC		


















































































































































specificity	 75%,	 accuracy	 75%	 (Table	 5.7).	 In	 the	 discovery	 cohort,	 ABC3D	 exhibited	 a	





























83	 80	 74	 88	 81	
ABC3D	
	












AAR	 >0.8	 46	 71	 47	 70	 62	
APRI	 >1.5	 11	 96	 63	 66	 66	
BARD	 >2	 76	 51	 47	 79	 60	
FIB4	 >2.67	 21	 94	 67	 68	 68	
NFS	 >0.676	 27	 95	 78	 70	 71	
ADAPT	 >6.3	 76	 75	 63	 86	 76	
FIB-C3	 >-0.4	 75	 75	 62	 84	 75	




























































































































































































5	 15	 99	 15	 98	 19	 96	 22	 96	 14	 98	
10	 27	 97	 26	 96	 33	 92	 38	 92	 26	 96	
15	 37	 95	 36	 94	 44	 87	 49	 88	 36	 94	
20	 46	 93	 45	 91	 52	 83	 57	 84	 45	 92	
25	 53	 91	 52	 89	 59	 79	 64	 80	 52	 90	
30	 59	 89	 58	 86	 65	 74	 70	 75	 58	 87	
35	 65	 87	 63	 83	 70	 69	 74	 71	 63	 85	
40	 69	 84	 68	 80	 75	 65	 78	 66	 68	 82	
45	 74	 81	 73	 77	 78	 60	 82	 61	 72	 78	





























5	 25	 99	 12	 98	 11	 98	 14	 98	 12	 97	
10	 42	 97	 23	 97	 21	 95	 26	 95	 22	 94	
15	 53	 96	 32	 95	 30	 93	 36	 92	 31	 91	
20	 62	 94	 40	 93	 38	 90	 45	 90	 39	 88	
25	 68	 92	 47	 91	 46	 87	 51	 87	 46	 85	
30	 73	 90	 53	 88	 51	 84	 57	 84	 52	 81	
35	 78	 88	 59	 86	 57	 81	 63	 80	 58	 78	
40	 81	 85	 64	 83	 62	 78	 68	 76	 63	 74	
45	 84	 82	 69	 80	 67	 74	 72	 73	 68	 70	
































Male	 Female	 BMI	<25	 BMI>25	
	
	





20	 87	 76	 31	 51	 56	 4	 103	
AUROC	 0.84	 0.92	 0.81	 0.83	 0.72	 0.84	 0.81	 0.88	 0.82	
Sensitivity	 74	 90	 71	 91	 35	 73	 77	 25	 77	
Specificity	 75	 72	 77	 41	 94	 77	 73	 96	 73	
PPV	 63	 56	 65	 64	 58	 58	 68	 50	 63	








































Male	 Female	 BMI	<25	 BMI>25	
	
	





20	 87	 76	 31	 51	 56	 4	 103	
AUROC	 0.81	 0.91	 0.79	 0.76	 0.77	 0.83	 0.77	 0.88	 0.79	
Sensitivity	 64	 85	 64	 91	 13	 67	 69	 25	 70	
Specificity	 76	 76	 75	 30	 99	 78	 71	 96	 73	
PPV	 61	 59	 62	 60	 80	 57	 65	 50	 61	
NPV	
	
79	 93	 77	 74	 82	 84	 75	 88	 80	
Accuracy		
	







was	 replicated	 in	 the	validation	 cohort	 (n=298),	AUROC	=	0.76,	 sensitivity	76%,	 specificity	
61%,	accuracy	63%	(Table	5.3).	Assessing	the	FIBC3	and	ABC3D	scores	in	the	complete	cohort	
(n=449),	the	results	are	shown	in	Table	5.12.	In	general,	tests	incorporating	PROC3	performed	


























	 PPV	 NPV	 Sensitivity	 Specificity	 Accuracy	 Number	missed	
cases		
AAR>0.8	 59	 55	 44	 70	 57	 126	
APRI>1.5	 79	 52	 10	 97	 53	 203	
BARD>2	 61	 66	 72	 54	 63	 63	
FIB4>2.67	 76	 53	 17	 95	 56	 187	
NFS>0.676	 78	 54	 20	 94	 57	 180	
ADAPT>6.3	 73	 67	 61	 77	 69	 87	
FIBC3	>-0.4	 74	 68	 64	 77	 71	 81	
ABC3D	>3	 73	 66	 59	 78	 69	 92	
***	tdNASH	F3-F4	
	
AAR>0.8	 25	 81	 44	 65	 60	 53	
APRI>1.5	 18	 79	 43	 94	 75	 89	
BARD>2	 27	 87	 74	 45	 51	 24	
FIB4>2.67	 22	 79	 12	 89	 73	 83	
NFS>0.676	 26	 80	 16	 88	 73	 79	
ADAPT>6.3	 32	 87	 65	 64	 64	 33	
FIBC3	>-0.4	 32	 88	 67	 63	 64	 31	
ABC3D	>3	 31	 86	 61	 65	 64	 37	
****	tdNASH	Cirrhosis	(F4)	
	
AAR>0.8	 20	 92	 61	 66	 65	 22	
APRI>1.5	 46	 90	 23	 96	 87	 43	
BARD>2	 18	 95	 84	 45	 50	 9	
FIB4>2.67	 40	 91	 36	 92	 85	 36	
NFS>0.676	 40	 92	 41	 91	 85	 33	
ADAPT>6.3	 25	 97	 86	 64	 67	 8	
FIBC3	>-0.4	 27	 98	 93	 64	 67	 4	











The	 residual	 cohort	of	NAFLD	patients	with	 intermediate	 scores	were	 then	 subject	 to	 the	
ABC3D	diagnostic	algorithm	to	detect	cases	of	advanced	fibrosis	(Table	5.13	and	Table	5.14).	
With	the	application	of	sequential	testing,	the	accuracy	improved	for	the	NFS	from	52	to	70%	
















(n=449)	 TP	 TN	 FP	 FN	 Total	 PPV	 NPV	 Sen	 Spec	 Accuracy	
Negative	(n=206)	
NFS<-1.433	
0	 175	 0	 31	 206	 0	 85	 0	 100	 85	
Positive	(n=258)	
NFS	>	0.676	






69	 58	 36	 22	 185	 66	 73	 76	 62	 69	


































65	 54	 20	 20	 159	 77	 83	 76	 73	 75	













































Age	(years)	 51+/-13	 51+/-12	 51.8+/-13	 0.206	
Gender	(male)	 211(59%)	 72(58	%)	 139(59	%)	 0.807	
BMI	(Kg/m
2
)	 32.3+/-6.4	 32.6+/-6.1	 32.2+/-6.6	 0.383	
T2DM		 169(47%)	 199(47%)	 85(46%)	 0.918	
ALT	(U/l)	 71+/-43	 68+/-43	 73+/-43	 0.455	
High	ALT	(>40U/l)	 272(76%)	 96(77%)	 176(75%)	 0.642	
AST	(U/l)	 48+/-27	 48+/-28	 48+/-26	 0.597	
Albumin	(g/dl)	 44+/-4	 44+/-4	 44+/-4	 0.512	
Platelets	(X10
9
/l)	 228+/-71	 223+/-62	 230+/-75	 0.432	
Cholesterol	(mg/dl)	 7+/-12	 5+/-2	 7.2+/-14	 0.238	
Triglycerides	(mg/dl)	 3.5+/-16	 4.4+/-20	 3.0+/-13	 0.833	
Collagen	Pro-C3(ng/ml)	 19.3+/-15	 18.5+/-15	 19.8+/-15	 0.252	
Collagen	Pro-C6(ng/ml)	 9.9+/-4.7	 9.7+/-5.1	 10.0+/-4.5	 0.183	
P4NP7S	(ng/ml)	 272+/-148	 265+/-150	 275+/-148	 0.521	
C4M2	(ng/ml)	 27.2+/-10	 27.4+/-11	 27.0+/-9.8	 0.972	
C3M	(ng/ml)	 11.6+/-5	 11.5+/-4.6	 11.6+/-4.5	 0.819	
Fibrosis	Stage	(0/1/2/3/4)	 70/73/75/86/54	 19/29/28/32/16	 51/44/47/54/38	 0.454	
Steatosis	
0/1/2/3	
6/115/134/94	 3/38/43/38	 3/77/91/56	 0.475	
Ballooning	
0/1/2	
96/148/103	 27/55/40	 69/93/63	 0.228	
Lobular	Inflammation	
0/1/2/3	
34/175/117/21	 15/53/43/11	 19/122/74/10	 0.117	
NAS	 4+/-2	 5+/-2	 4+/-2	 0.510	
FIB4	 1.54+/-1.10	 1.56+/-1.16	 1.53+/-1.07	 0.865	 	








NAFLD	Fibrosis	Score	 -1.351+/-1.84	 -1.257+/-1.687	 -1.400+/-1.919	 0.080	
APRI	 0.698+/-0.50	 0.71+/-0.57	 0.69+/-0.45	 0.938	
ADAPT	Score	 6.38+/-2.29	 6.25+/-2.3	 6.45+/-2.31	 0.396	
BARD	Score	 2+/-1	 2+/-1	 2+/-1	 0.142	
Centrally	Read	Biopsies		 226(63	%)	 76	(61	%)	 150(64	%)	 0.562	
PNPLA3	
CC/GG/GC	
125/65/168	 41/26/57	 84/39/111	 0.458	
PNPLA3	
G-Dominant	
233	(65%)	 83	(67%)	 150	(64%)	 0.593	





































0.001	 	 	 	
Gender	 0.671	 0.323-
1.394	
0.284	 	 	 	


























0.792	 	 	 	
Triglycerides	 0.986	 0.945-
1.029	
































































































































































Sensitivity	 Specificity	 PPV	 NPV	 Accuracy	
PROC3PNPLA3	 0.90	 >-
1.04	
94	 68	 65%	 95%	 78%	
	 Cut-
off	
Sensitivity	 Specificity		 PPV	 NPV	 Accuracy	
AAR	
	
>0.8	 49%	 76%	 57%	 70%	 65%	
APRI	
	
>1.5	 12%	 98%	 79%	 63%	 64%	
BARD		
	
>2	 79%	 58%	 55%	 81%	 66%	
FIB4	
	
>2.67	 22%	 97%	 83%	 66%	 68%	
NFS	
	
>0.676	 30%	 96%	 85%	 68%	 70%	
ADAPT	
	
>6.3	 76%	 78%	 69%	 83%	 77%	
FIBC3	
	
>-0.4	 80%	 79%	 71%	 86%	 79%	
ABC3D	
	
>3	 74%	 74%	 65%	 81%	 74%	
PROC3PNPLA3	 >-1.04	 83%	
	

































































































































































532).	 This	 implies	 a	paradox	 that	makes	addressing	 the	need	 for	biomarkers	 all	 the	more	
challenging:	 the	histological	 reference	 standard,	 against	which	 a	 biomarker	 is	 assessed,	 is	
inherently	imperfect	and	unable	to	produce	a	completely	error-free	classification	with	respect	
to	the	presence	or	absence,	or	severity,	of	the	target	condition.	Semi-quantitative	histological	
grading	 conflates	 anatomical	 distribution	 of	 fibrosis	 with	 extent	 and	 imposes	 discrete	
categorical	staging	bins	on	what	are	continuous	variables	like	collagen	deposition	(45).	This	
inevitably	leads	to	discrepancies	due	to	inter-	and	intra-observer	judgement,	especially	at	the	
margins.	 It	 also	 blunts	 sensitivity	 as	 semi-quantitative	 grades	 fail	 to	 recognise	 modest	
differences	 in	 severity	 that	 do	 not	 transition	 across	 predefined	 but	 arbitrary	 categorical	
boundaries.	 This	 phenomenon	 is	 well	 illustrated	 by	 the	 breadth	 of	 disease	 that	 is	
encompassed	 by	 stage	 F3	 fibrosis	 in	 the	 NASH	 CRN	 classification	 (45)	 where	 histological	
portal-portal,	 central-central	 and/or	 portal-central	 bridging	 is	 the	 defining	 feature,	 yet	 no	
weight	 is	 given	 to	density	of	 collagen	deposition	or	 the	number	of	 “bridging” septae.	 The	
situation	 where	 an	 imperfect	 reference	 standard	 is	 used	 in	 place	 of	 a	 perfect	 standard,	
introduces	“imperfect	gold	standard	bias”. This	means	that	the	performance	of	the	new	test	
may	be	under-	or	over-estimated	and,	even	if	it	is	in	reality	a	better	measure	of	disease,	it	







Cognisant	of	 these	 challenges,	 this	 study	 reports	measurement	of	PROC3	 levels	 in	a	 large	























































In	 the	 validation	 cohort,	 FIBC3	performed	best	 correctly	 identifying	 75%	of	 patients,	with	
ABC3D	more	or	less	equivalent	correctly	identifying	72%	of	patients.	In	the	full	cohort	of	449	
patients,	 the	 FIBC3	 model	 identified	 254	 patients	 as	 not	 having	 advanced	 fibrosis	 (at	 a	
threshold	of	less	than	-0.4)	of	which	217	were	correctly	classified.	Therefore,	in	this	“low-risk	
cohort” the	 FIBC3	model	 could	 have	 correctly	 avoided	 a	 liver	 biopsy	 in	 85% of	 patients.	
Applying	the	same	analysis	to	ABC3D,	267	patients	were	identified	as	‘low-risk’ (score<3).	In	
this	cohort,	219	patients	were	correctly	staged	thus	potentially	correctly	avoiding	biopsies	in	












The	 point	 performance	 of	 diagnostic	 tests	 in	 terms	 of	 PPV/NPV	 are	 affected	 by	 pre-test	













































NAFLD	pathological	 assessment	 and	demonstrated	high	 kappa-value	 reproducibility	 (126).	
Moreover,	half	of	the	biopsies	across	all	sites	were	assessed	centrally.	While	this	certainly	
reduces	 the	 reader-related	 variability,	 it	 is	 still	 dependent	 on	 limitations	 intrinsic	 to	
histological	 classifications	 such	 as	 the	 semi-quantitative	 nature	 of	 fibrosis	 scoring	 and	 on	
sampling	variability	of	the	procedure.	These	limitations	are	common	to	all	biomarkers	that	
use	biopsy	as	the	reference	standard.	To	minimize	the	effects	of	inter-observer	variability	in	
fibrosis	 staging	 half	 the	 cohort	 across	 all	 centres	 had	 centrally	 reviewed	 liver	 biopsies	
confirming	high	 inter-observer	agreement.	Although	we	have	taken	measures	 to	minimize	
inter-observer	 variability	 in	 the	 histological	 scoring,	 and	 concordance	 between	 liver	














(CAP)	 certified	 lab	 by	 staff	 blinded	 to	 the	 clinical	 data	 and	 results	 sent	 to	 a	 separate,	
independent	 centre	 for	 statistical	 analysis.	 Protein	 finger	 print	 technology	 has	 been	
developed	 to	 produce	 a	 reliable	 assay	 for	 PROC3	 measurement	 (513).	 Our	 model,	 in	
comparison	to	previous	complex	biomarker	panels	(e.g.	ELF™, Fibrotest™) includes	only	one	
variable	that	is	not	routinely	measured	in	a	clinical	setting.	It	is	regrettable	that	this	study	was	
































































































































































































































































































































Primer		 Id		 Sequence		 Nt		 Tm,	
ºC		
%GC		
PCR		 MZ1.1-F		 TTATGTGAATTTAGGAAGTAGAGG		 24		 62.7		 33.3		
PCR		 MZ1.1-R	 AAACCATTAACTCCAAAAAAAAAT		 24		 65.3		 20.8		










Primer		 Id		 Sequence		 Nt		 Tm,	
ºC		
%GC		
PCR		 MZ3.1-F		 AGTAATTTAGAGTTTGGGAGTTAG		 24		 61.3		 33.3		
PCR		 MZ3.1-R1		 TCAACAATCCTAACCTTTCTCTAT		 24		 64.3		 33.3		











Primer		 Id		 Sequence		 Nt		 Tm,	
ºC		
%GC		
PCR		 MB3.3F1		 GAGAGTAGGGTTTTGAGGTAGGAA		 24		 68.0		 45.8		
PCR		 MB3.3R1		 TACCTCCCCATCCCTCTACC		 20		 69.0		 60.0		







Primer		 Id		 Sequence		 Nt		 Tm,	
ºC		
%GC		
PCR		 MZ5.4-F	 TGTTATTATTGGTTTTGGAAGAAA		 24		 65.7		 25.0		
PCR		 MZ5.4-R		 CCACAATACCCAACCTAATTATCT		 24		 66.3		 37.5		








Primer		 Id		 Sequence		 Nt		 Tm,	
ºC		
%GC		
PCR		 MZ6.1-F		 AAATTAGTTGAGTGTGGTGGTATA		 24		 63.5		 33.3		
PCR		 MZ6.1-R		 ACAAACCCAACATTCTTTAATTTA		 24		 64.9		 25.0		







Primer		 Id		 Sequence		 Nt		 Tm,	
ºC		
%GC		
PCR		 MZ6.3-F		 ATTTGTGTTGTGGAAAGGTTTATT		 24		 66.8		 29.2		
PCR		 MZ6.3-R		 CAAAATCTCACTACAACCAAATTT		 24		 65.4		 29.2		















Primer		 Id		 Sequence		 Nt		 Tm,	ºC		 %GC		
PCR		 MB6.1F1		 GGTTTGATGGTTAGATGGGTATG		 23		 68.3		 43.5		
PCR		 MB6.1R1		 AAAAAACAAACCTACCCCTTTTC		 23		 67.6		 34.8		






Primer		 Id		 Sequence		 Nt		 Tm,	ºC		 %GC		
PCR		 MB6.3F1		 TTTGAGAATTAGGAAAGTTGATGG		 24		 67.5		 33.3		
PCR		 MB6.3R1		 AAATAAACCTCATCCAATCCATTA		 24		 66.7		 29.2		










































































columns; desulphonated	and	washed	according	to	manufacturer’s protocol, eluted	in	






























































































































































N=22	 Mild	NAFLD	fibrosis	(F0–2)	 Advanced	NAFLD	fibrosis	(F3–F4)	 p	Value	
	 n=14	 n=12	 	
Age	(years)	 57±7	 59±12	 0.56*	
Gender	(male)	 29%	 67%	 0.052†	
BMI	(kg/m2)	 36.0±5.5	 36.0±7.3	 0.996*	
Diabetes	 50%	 67%	 0.39†	
ALT	(IU/L)	 55±37	 62±19	 0.55*	
AST	(IU/L)	 39±13	 53±12	 0.01*	
ALB	(g/L)	 46±3	 45±4	 0.37*	
Platelets	(×109/L)	 234±54	 223±70	 0.67*	
AST/ALT	ratio	 0.80±0.23	 0.91±0.27	 0.29*	
































































MZ	3.1	 1	 CpG	1	 0.86079	
MB	3.3	 1	 CpG1	 0.980	
MZ	5.4	 1	 CpG	1	 0.95609	
MZ	6.1	 1	 CpG	1	 0.99716	
MZ	6.3	 1	 CpG	1	 0.98835	
MB	6.1	 1	 CpG	1	 0.976	























Primer	MZ	1.1	 	 	 	
CpG	1	 84	+/-	20%	 81	+/-	29%	 ns	
CpG2	 35	+/-	32%	 38+/-36%	 ns	
DMR	3	
Primer	MZ	3.1	 82	+/-	13%	 79	+/-	13%	 ns	








Primer	MZ	5.4	 77	+/-	16%	 87	+/-	17	 Inverse		
DMR	6	
Primer	MZ	6.1	 69	+/-	16%	 72	+/-	9%	 Inverse	
Primer	MZ	6.3	 87	+/-	11%	 86	+/-	9%5	 ns	
Primer	MB	6.1	 47	+/-	15%	 43	+/-	16	 ns	
Primer	MB	6.3	 	 	 	
CpG	1	 86+/-	7%	 89	+/-	5%	 Inverse	













































































































































































































































































































The	 immense	 complexity	 in	 CpG	 methylation	 analysis	 often	 produces	 weak,	 non-specific	
correlations	between	CpG	methylation	and	gene	expression	data	 limiting	the	derivation	of	
robust	 conclusions.	 While	 still	 considering	 individual	 CpG	 sites,	 practices	 have	 evolved	
whereby	 the	 genome	 is	 now	 scanned	 for	 clusters	 of	 differentially	 methylated	 CpG	 sites	






the	 converted	 DNA	 sequence	 rather	 than	 read	 counts.	 Direct	 genome	 sequencing	 also	
provides	 more	 complete	 and	 unbiased	 genomic	 coverage	 with	 higher	 accuracy,	 even	 in	
comparison	to	the	most	advanced	high-density	gene	arrays	such	as	the	 Infinium	450	Bead	
chip	 array	 (Illumina),	 which	 detects	 only	 1.5%	 of	 CpGs	 in	 the	 human	 genome	 (608).	 The	






























To	 detect	DNA	methylation	 changes	 at	 baseline	 that	 distinguishes	 high	 risk	 from	 low	 risk	
NAFLD,	 the	 study	 cohort	 will	 be	 divided	 into	 2	 phenotypically	 distinct	 two	 groups.	 BS	





3. Consider	 potential	 links	 to	 novel	 pathways	 that	 control	 biological	 processes	
underpinning	low	and	high	risk	disease		
	




















































































































































































































1(b)	 4	 72	months	 3	 Progressor	 High	
1(a)	 3	 84	months	 2	 Progressor	 High	
1(b)	 4	 48	months	 3	 Progressor	 High	
1	(b)	 3	 120	months	 2	 Progressor		 High	
0	 0	 24	months	 0	 Stable	 Low		
1	(a)	 1	 144	months	 0	 Stable	 Low		
1	(a)	 1		 48	months	 0	 Stable	 Low		


















Male,	n,	(%)	 4	(50%)	 2	(50%)	 2	(50%)	 1.000	
Diabetes,	n,	(%)	 6	(75%)	 3	(75%)	 3	(75%)	 1.000	
Weight	(Kg)	 90	+/-	15	 87+/	19	 93+/10	 0.583	
Body	mass	index		 34	+/-	4		 34+/	6	 35+/3	 0.700	
ALT	(IU/L)	 94	+/-66	 80+/29	 109+/94	 0.574	
AST	(IU/L)	 65	+/-49	 57+/13	 69+/68	 0.823	
ALP	(IU/L)	 94	+/-25		 89+/34	 102	+/	11	 0.556	
Albumin	(g/L)	 46	+/-2	 47+/2	 44+/	2	 0.06	
Platelets	(x109/L)	 259	+/-49		 254+/73	 264	+/16	 0.797	
HBA1c	 6+/-0.8		 6+/1	 6	+/0.5	 0.411	
Ferritin	(ug/L)	 154	+/-134		 91+/66	 239	+/	168	 0.161	
AST:	ALT	(ratio)	 0.66+/-0.17	 0.71+/0.22	 0.62	+/	0.15	 0.557	
FIB4	 1.3	+/-0.54	 1.34+/0.61	 1.22	+/	0.59	 0.803	
NAFLD	Fibrosis	
Score	
-1.48	+/-1		 -1.70+/1.3	 -1.32	+/	0.90	 0.658	
Steatosis	
(0/1/2/3)	
(0/2/5/1)	 0/0/3/1	 0/2/2/0	 0.202	
Ballooning	
(0/1/2)	




(1/6/1/0)	 1/2/1	 0/4/0/0	 0.264	
Fibrosis	Stage	
(0/1/2/3/4)	
(1/7/0/0)	 0/4/0/0	 1/3/0/0	 0.285	
NAS	 4+/-4	(2-6)	 4+/2	 3+/	1	 0.414	
NASH	(NAS>4)	 6(75%)	 3	(75%)	 3	(75%	 1.000	
PNPLA3	G	Allele	
Positive	




























































































The	 statistical	method	 used	 to	 detect	 differential	methylation	 in	 this	 study	was	 BSmooth	
(compatible	with	WGBS	data).	This	platform	involves	a	smoothing	step	(polynomial	logistic	
regression	 with	 tri-cube	 weight-	 using	methylation	measures	 from	 neighbouring	 sites)	 to	












































































































































DAVID	 Bioinformatics	 Resources	 (DAVID)	 at	 http://david.abcc.ncifcrf.gov	 is	 an	 integrated	
biological	 analytical	 resource	 powered	 to	 systematically	 extract	 biological	 meaning	 from	
omics	data.		
Serial	pathway	mining	tools	employed	within	DAVID	include	Gene	Functional	Classification	















































Category	 Term	 Count	 %	 P-Value	
KEGG_PATHWAY	 Wnt	signalling	pathway	 7	 0	 3.80E-03	
KEGG_PATHWAY	 Pathways	in	cancer	 11	 0	 9.80E-03	
KEGG_PATHWAY	 Hippo	signalling	pathway	 6	 0	 2.40E-02	
KEGG_PATHWAY	 Vascular	smooth	muscle	contraction	 5	 0	 3.80E-02	
KEGG_PATHWAY	 Aldosterone	synthesis	and	secretion	 4	 0	 5.80E-02	
KEGG_PATHWAY	 Melanogenesis	 4	 0	 9.50E-02	











Category	 Term	 Count	 %	 P-Value	
GOTERM_MF_DIRECT	 Protein	binding	 127	 65.5	 3.80E-07	
GOTERM_CC_DIRECT	 Cytoplasm	 85	 43.8	 2.50E-06	
GOTERM_CC_DIRECT	 Nucleoplasm	 53	 27.3	 1.10E-05	
GOTERM_CC_DIRECT	 Nucleus	 81	 41.8	 1.40E-04	
GOTERM_BP_DIRECT	 Chromatin	organization	 5	 2.6	 1.10E-03	
GOTERM_BP_DIRECT	 Activation	of	phospholipase	C	activity	 4	 2.1	 2.60E-03	
GOTERM_BP_DIRECT	 Positive	regulation	of	fibroblast	proliferation	 5	 2.6	 2.70E-03	





























UP_SEQ_FEATURE	 repeat:	WD	3	 12	 3.10E-04	 Major	pathway	of	rRNA	processing	in	the	
nucleolus	and	cytosol	
UP_SEQ_FEATURE	 repeat:	WD	2	 12	 4.10E-04	 Deubiquitination	
UP_SEQ_FEATURE	 repeat:	WD	1	 12	 4.10E-04	 Response	to	elevated	platelet	cytosolic	Ca2+	
UP_KEYWORDS	 WD	repeat	 12	 4.50E-04	 	
UP_SEQ_FEATURE	 repeat:	WD	5	 11	 4.60E-04	 Chromatin	organization	
UP_SEQ_FEATURE	 repeat:	WD	8	 6	 6.40E-04	 RAF/MAP	kinase	cascade	
INTERPRO	 WD40	repeat,	 9	 7.40E-04	 VEGFA-VEGFR2	Pathway	











UP_SEQ_FEATURE	 repeat:	WD	7	 8	 1.90E-03	 Chromatin	organization	
SMART	 WD40	 11	 2.00E-03	 	
UP_SEQ_FEATURE	 repeat:	WD	6	 9	 2.10E-03	 Cilium	Assembly	
UP_SEQ_FEATURE	 repeat:	WD	11	 4	 4.90E-03	 	
UP_SEQ_FEATURE	 repeat:	WD	10	 4	 5.40E-03	 	































GOTERM_BP_DIRECT	 Circadian	regulation	of	gene	expression	 4	 2.1	 4.10E-
03	














GOTERM_BP_DIRECT	 Negative	regulation	of	insulin	secretion	 15	 7.7	 1.10E-
02	
GOTERM_BP_DIRECT	 Autophagy	 43	 22.1	 1.50E-
02	









































Category	 Term	 Count	 %	 P-Value	






















UP_SEQ_FEATURE	 Zinc	finger	region:	NR	C4-type	 5	 6.30E-04	
UP_SEQ_FEATURE	 DNA-binding	region:	Nuclear	receptor	 5	 6.30E-04	
INTERPRO	 Zinc	finger,	nuclear	hormone	receptor-type	 5	 8.80E-04	




SMART	 ZnF_C4	 5	 1.40E-03	
SMART	 HOLI	 5	 1.60E-03	
GOTERM_MF_DIRECT	 Steroid	hormone	receptor	activity	 5	 1.90E-03	












GOTERM_MF_DIRECT	 sequence-specific	DNA	binding	 6	 5.40E-01	
























































































































































































































































































































































































for	 simple	and	accurate	non-invasive	 tests	 to	 stage	 liver	 fibrosis,	 risk	 stratify	 and	monitor	
response	to	treatment	and	so	 improve	patient	QoL.	This	 is	particularly	 important	with	the	
recent	development	of	several	new	drugs	for	NAFLD	that	are	going	through	advanced-phase	









studies	have	described	 the	 role	of	epigenetic	mechanisms,	 in	particular	DNA	methylation,	
may	have	in	fibrosis	progression	in	chronic	liver	disease.	We	looked	to	validate	previous	in-
house	work	that	described	novel	methylation	fibrosis	diagnostic	signatures	to	move	closer	to	
translating	 these	 findings	 into	 a	 potential	 non-invasive	 biomarker	 of	 liver	 fibrosis.	 In	 an	
additional	novel	proof	of	concept	study,	we	then	characterised	a	DNA	methylation	signature	

















































at	 time	of	genomic	DNA	extraction	which	will	be	available	 for	 further	 studies.	 Finally,	 the	
targets	discovered	in	these	studies	may	also	be	applicable	to	other	fibrotic	disease	such	as	















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Health-related Quality of Life in Nonalcoholic Fatty Liver
Disease Associates With Hepatic Inflammation
Yvonne Huber,* Marie Boyle,‡,§ Kate Hallsworth,‡,§ Dina Tiniakos,‡,§,k
Beate K. Straub,¶ Christian Labenz,* Christian Ruckes,# Peter R. Galle,*
Manuel Romero-Gómez,** Quentin M. Anstee,‡,§,b and Jörn M. Schattenberg,*,b on
behalf of the EPoS Consortium Investigators
*I. Department of Medicine, University Medical Centre of the Johannes Gutenberg-University Mainz, Mainz, Germany; ‡Institute
of Cellular Medicine, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom; §Liver Unit,
Newcastle Upon Tyne Hospitals NHS Trust, Freeman Hospital, Newcastle upon Tyne, United Kingdom; kDepartment of
Pathology, Aretaieion Hospital, Medical School, National & Kapodistrian University of Athens, Athens, Greece; ¶Institute of
Pathology, University Medical Centre of the Johannes Gutenberg-University Mainz, Mainz, Germany; #Interdisciplinary Centre
for Clinical Trials (IZKS), University Medical Centre of the Johannes Gutenberg-University Mainz, Mainz, Germany; and **Unit for
the Clinical Management of Digestive Diseases, Centro para la Investigacion Biomedica en Red de Enfermedades Hepaticas y
Digestivas (CIBEREHD), Virgen del Rocio University Hospital, University of Seville, Seville, Spain
BACKGROUND & AIMS: Chronic liver disease has negative effects on health-related quality of life (HRQL). We analyzed
data from the European non-alcoholic fatty liver disease (NAFLD) registry to assess the effects
of NAFLD on HRQL.
METHODS: We collected data from 304 patients (mean age, 52.3 – 12.9 years) with histologically de!ned
NAFLD enrolled prospectively into the European NAFLD Registry in Germany, the United
Kingdom, and Spain. The chronic liver disease questionnaire (CLDQ) was completed within 6
months of liver biopsy collection.
RESULTS: The mean CLDQ overall score was 5.0 – 1.2, with the lowest score in the category fatigue (4.3 –
1.6) and the highest scores for activity (5.4 – 1.4). Women had signi!cantly lower CLDQ scores
than men (4.6 – 1.3 vs 5.3 – 1.1; P < .001). We found negative correlations between CLDQ scores
and presence of obesity (P < .001), type 2 diabetes (P < .001), and dyslipidaemia (P < .01). There
was a negative correlation between level of aspartate aminotransferase, but not alanine
aminotransferase, and HRQL. Higher histological score of steatosis (1 vs 3) resulted in lower
mean CLDQ score (5.3 – 1.1 vs 4.5 – 1.4; P < .01); higher level of lobular in"ammation (0 vs 3)
also resulted in lower mean CLDQ score (5.3 – 1.2 vs 3.9 – 1.8; P <. 001). In contrast, advanced
!brosis (F3–4) compared to early or intermediate !brosis (F0–2) had no signi!cant effect on
mean CLDQ score (4.9 – 1.2 vs 5.1 – 1.3; P [ .072). In multivariate analysis, patients sex, age,
presence of type 2 diabetes, and in"ammation were independently associated with low HRQL.
CONCLUSION: In an analysis of data from the European NAFLD registry, we observed a substantial burden of
symptoms in patients. In addition to age, sex, and the presence of diabetes, detection of lobular
in"ammation in biopsies correlated with lower HRQL.
Keywords: Nonalcoholic Steatohepatitis; Patient-Reported Outcomes; Cirrhosis; Emotional Function.
See editorial on page 1950; see related article
on page 2093 in this issue of Clinical
Gastroenterology and Hepatology.
Nonalcoholic fatty liver disease (NAFLD) is thefastest growing and most common cause of liver
disease globally.1 It is estimated to affect up to 30% of
the population, and a continued increase has been pre-
dicted in the coming years.2 Distinction between NAFLD
bAuthors share co-senior authorship.
Abbreviations used in this paper: ALT, alanine aminotransferase; AST,
aspartate aminotransferase; BMI, body mass index; CLDQ, Chronic Liver
Disease Questionnaire; HbA1c, glycosylated hemoglobin; HCV, hepatitis C
virus; HRQL, health-related quality of life; NAFLD, nonalcoholic fatty liver
disease; NASH, nonalcoholic steatohepatitis; PRO, patient-reported
outcome; UK, United Kingdom.
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and nonalcoholic steatohepatitis (NASH) can only be
performed on liver histology, with NASH requiring the
presence of lobular in!ammation and hepatocyte
ballooning in addition to hepatic steatosis.3 The histo-
logic stage of "brosis as currently de"ned in a 5-tier
(0–4) histologic staging in the 2 most commonly used
histologic scoring systems, the NASH CRN activity score4
and the Steatosis-Activity-Fibrosis score,5 correlates with
hepatic morbidity and overall mortality.6 Today, NASH is
the most rapidly growing cause and the second leading
indication for liver transplantation in the United States.7
Overall mortality in patients with NASH is strongly in!u-
enced by comorbidities, including abdominal obesity,
arterial hypertension, insulin resistance, and dyslipide-
mia,8 all of which are highly prevalent in real-world co-
horts, in particular in patients with advanced "brosis.9
Patients with chronic liver disease exhibit nonspeci"c
symptoms but commonly report fatigue and abdominal
discomfort. These symptoms can add to the disease
burden and lead to a signi"cant impairment in the
quality of life.10 In chronic hepatitis C, it has been pro-
posed that these effects add to the economic burden of
the disease by increasing leave time from work and loss
in productivity.11 Previous studies in patients with
NAFLD observed an association between fatigue and
daytime sleepiness with the degree of insulin resistance
but not with the histologic disease severity.12 In a U.S.
population, NAFLD and NASH caused an incremental
decrease of physical health scores, but no association of
NASH or mental health scores with the degree of "brosis
was reported.13 With the emergence of medical therapy
for NASH, it will be of importance to identify patients
with the highest unmet need for treatment. Patient-
reported outcomes (PROs) are an important tool to
assess the individual burden of a disease. Different tools
have been developed to assess health-related quality of
life (HRQL). The Chronic Liver Disease Questionnaire
(CLDQ) is a liver disease–speci"c, multidimensional
concept, which evaluates emotional, mental, physical,
and social functioning categories.14 Therefore, it more
speci"cally addresses symptoms of patients with chronic
liver disease, including extrahepatic manifestations,
compared with traditional HRQL measures such as the
SF-36 health survey questionnaire.15–17 Lower CLDQ
scores indicate worse self-reported quality of life. Using
the CLDQ, a decreased HRQL was observed in a cohort
study on 150 patients with non-infectious chronic liver
disease, and frequently reported symptoms included fa-
tigue, abdominal discomfort, and anxiety.18 In patients
with hepatitis C virus (HCV) an improvement of HRQL
was detectable by using the CLDQ after cure.19 Viremia
and hepatic in!ammation are likewise associated with
impaired HRQL in patients with chronic hepatitis B vi-
rus.20 With ongoing re"nement of the PRO instruments,
the NASH CLDQ was recently introduced.21 Beyond
disease-speci"c aspects, HRQL can be in!uenced by na-
tional and social factors, but generalizability has recently
been shown for other tests, suggesting that PROs can be
reliably assessed and compared even between different
countries.22 The aim of this prospective study was to
determine factors that affect HRQL in an European
population with histologically de"ned NAFLD.
Materials and Methods
Patient Characteristics
Patients with NAFLD were recruited at the University
Medical Centre of the Johannes Gutenberg-University,
Mainz, Germany, at the Freeman Hospital Liver Unit, New-
castle Upon Tyne Hospitals NHS Trust, Newcastle upon
Tyne, United Kingdom (UK), and at the University Hospital
of the University of Seville, Spain, as part of the prospec-
tively enrolling European NAFLD Registry, after written
informed consent. Permission was obtained from the
respective ethical commissions: Ethikkommission der
Landesärztekammer Rheinland-Pfalz (Germany), theNorth
East–Tyne &Wear South Research Ethics Committee (UK),
and the Spanish authorities. Other causes of liver disease
were ruled out by serologic testing; thresholds for alcoholic
consumption were de"ned according to European Associ-
ation for the Study of the Liver guidelines.23 The prevalence
of type 2 diabetes, arterial hypertension, and hyperlipid-
emia and the presence ofmetabolic syndromewerede"ned
according to the Joint Scienti"c Statement for Harmonizing
the Metabolic Syndrome.24 Laboratory results included
alanine aminotransferase (ALT), aspartate aminotrans-
ferase (AST), g-glutamyl transferase, albumin, platelet
count, ferritin, and glycosylated hemoglobin (HbA1c) and
were obtained within 30 days of liver biopsy.
What You Need to Know
Background
We analyzed data from the European nonalcoholic
fatty liver disease (NAFLD) registry to assess the
effects of this disease on health-related quality of life
(HRQL).
Findings
In an analysis of data from 304 patients with NAFLD
in Europe, we found a substantial symptom burden;
the mean CLDQ overall score was 5.0 ! 1.2, with the
lowest scores for fatigue (4.3 ! 1.6). In addition to
age, sex, and the presence of diabetes, lobular
in!ammation detected in liver biopsies correlated
with lower HRQL.
Implications for patient care
Patients with NAFLD have lower HRQL, especially
those who are older, women, or with comorbidities
or more advanced disease. HRQL might be used to
determine patient bene"t from pharmacologic treat-
ment or to select patients for treatment.












Liver histology was assessed by central scoring from
expert histopathologists who have met in person and
synchronized (B.S., D.T.). NASH was diagnosed and
scored according to the NASH CRN criteria.4 Histologic
scoring included hepatic steatosis grade 1, 5%–33%; 2,
33%–66%; and 3, >66% of hepatocytes affected. Also
included were lobular in!ammation grade 0, no in!am-
matory foci; grade 1, <2 foci per 200! "eld; grade 2, 2–4
foci per 200! "eld; and grade 3, >4 foci per 200! "eld;
ballooning grade 0, no ballooned hepatocytes; grade 1,
few ballooned hepatocytes; and grade 2, many/promi-
nent ballooned hepatocytes; "brosis stage (F) 0, no
"brosis; F1, perisinusoidal, perivenular, or portal/peri-
portal "brosis; F2, perisinusoidal and portal/periportal
"brosis; F3, bridging "brosis; and F4, cirrhosis. The
NAFLD activity score was calculated as the sum of the
scores for steatosis (1–3), lobular in!ammation (0–3),
and ballooning (0–2), ranging from 1 to 8.4
Chronic Liver Disease Questionnaire
For HRQL the liver disease–speci"c questionnaire
CLDQ was used in the respective language.17,25 The
CLDQ consists of 29 items on a 7-point Likert scale
ranging from 1 (all of the time) to 7 (none of the time)
representing the frequency of clinical symptoms and
emotional problems associated with liver diseases in the
last 2 weeks. It is divided into 6 subscale scores
(abdominal symptoms, fatigue, systemic symptoms, ac-
tivity, emotional functioning, worry) and a CLDQ overall
score. By dividing each domain score by the number of
items in the domain, CLDQ results can be presented on a
1–7 scale, with 1 indicating worst HRQL (bad) and 7
indicating best HRQL (good). Patients completed the
questionnaire during outpatient visit within 6 months of
liver biopsy. A minimal clinically important difference of
0.5 in the CLDQ was considered clinically relevant.26
Statistical Analysis
Descriptive statistics were computed for all variables.
Spearman’s rank correlation coef"cient was calculated to
compare lab values and CLDQ scores. Univariate
regression analysis was used to examine association
between 2 variables. Differences between 2 groups were
calculated by Mann-Whitney U rank test or the Fisher
exact test. The c2 test, respectively. Kruskal-Wallis rank
test was used for multi-group comparison. Analysis of
covariance was performed for multivariate testing, ac-
counting for the confounders including country, gender,
age, body mass index (BMI), and type 2 diabetes. All tests
were two-tailed, with signi"cant P value de"ned as <.05.
Univariate analyses were performed by using IBM SPSS
Statistic Version 21.0 (Armonk, NY.). The analysis of
covariance was performed by means of SAS, Version 9.4
(SAS Institute, Cary, NC). All authors had access to the




A total of 304 patients were included in the study,
154 from the UK, 133 from Germany, and 17 from Spain.
The mean age was 52.3 ("12.9) years, and 53.3% (n #
162) were male. The majority of patients (n # 228,
75.0%) were obese, with a median BMI of 33.3 kg/m2
(interquartile range, 30.0–37.5). Demographic data,
characteristics of liver function, histopathological fea-
tures, and differences between the countries are pre-
sented in Table 1. The majority of patients had moderate
steatosis (grade 2, n # 152, 51.4%), none or low-grade
lobular in!ammation (grade 0 or 1, n # 162, 54.7%),
and none or low-grade "brosis stage (F0-2, n # 177,
58.2%) on liver biopsy.
Differences in Health-Related Quality of Life in
Europe
A comparison between the 3 enrolling European
countries showed signi"cant differences between the
populations (Table 1). Patients in the UK (median
[range], 56 years [17–77]) and Spain (61 years [33–74])
were older compared with the entire population. Like-
wise, rates of obesity (total cohort vs UK, 75% vs 86%; P
< .001) and type 2 diabetes (total cohort vs UK, 51.3% vs
61.7%; P < .01) were higher, whereas arterial hyper-
tension (total cohort vs UK, 56.5% vs 66.8%; P < .001)
was lower in the UK cohort. Interestingly, there were
also signi"cant differences in HRQL between the 3 Eu-
ropean countries, and the UK exhibited the lowest CLDQ
overall score (mean [standard deviation], 4.73 ["1.3] vs
4.99 ["1.2]; P < .01) (Supplementary Table 1).
Health-Related Quality of Life and In!uencing
Factors
Mean CLDQ overall score was 4.99 ("1.2) in the
entire study population. The lowest scores were re-
ported in the subcategory "fatigue" with a value of 4.31
("1.6), followed by "emotional functioning” with 4.93
("1.5). “Abdominal symptoms” and “activity” showed
the highest values with 5.33 ("1.6) and 5.43 ("1.4),
respectively (Table 2). Women exhibited a signi"cantly
lower CLDQ overall score than men (mean [SD], 4.62
["1.3] vs 5.31 ["1.1]; P < .001). Also, all CLDQ subscale
scores including abdominal symptoms, fatigue, systemic
symptoms, activity, emotional functioning, and worry
were signi"cantly lower in women compared with
men, with a minimal clinically important difference >0.5











(P < .01) (Table 2). No correlation between CLDQ
overall score and age existed (Table 3). There was a
negative correlation between overall CLDQ score
and obesity (P < .001), type 2 diabetes (P < .001),
and dyslipidemia (P < .01) (Table 3). AST (r ! –0.12;
P < .05), ferritin (r ! 0.166; P < .01), and HbA1c (r !
–0.26; P < .001) correlated with CLDQ overall score
signi!cantly, whereas there was no correlation regarding
ALT (r ! 0.04) or gamma-glutamyl transferase (r !
–0.08) (Table 3). With regard to the subscale scores, fa-
tigue scored the lowest compared in all countries
(Supplementary Table 1).
Impact of Histologic Features of Nonalcoholic
Fatty Liver Disease on Health-Related Quality of
Life
NASH was present in 210 patients (69.1%), with no
in"uence of gender. Obesity (54.9% vs 20.1%; P < .05)
and type 2 diabetes (39.9% vs 11.5%; P < .01) were
more prevalent in NASH compared with NAFL, whereas
age, hypertension, dyslipidemia, and hyperferritinemia
were not different. AST (P < .001), ALT (P < .05), and
HbA1c (P < .001) were signi!cantly higher in NASH
compared with NAFL. NASH was associated with a
signi!cantly lower HRQL compared with patients with
NAFL (mean [standard deviation], 4.85 ["1.3] vs 5.31
["1.1]; P < .01). In addition, patients with NASH scored
signi!cantly lower on all CLDQ subscales except for
“abdominal symptoms” and “emotional function”
(Table 4). By using a minimal clinically important dif-
ference threshold of 0.5, the subscales “fatigue” and
“systemic symptoms” reached clinically meaningful dif-
ferences, whereas CLDQ overall score (D 0.46) showed a
clear trend toward impaired HRQL in NASH.
The histologic features of NAFLD on liver biopsy had
a signi!cant impact on HRQL. Patients with more severe
hepatic steatosis exhibited a lower HRQL score (grade 3
vs 1, 4.5 ["1.4] vs 5.3 ["1.1]; P < .05). Similarly, more
severe ballooning (grade 2 vs 0, 4.7 ["1.3] vs 5.3 ["1.2];
Table 1. Demographic Data, Characteristics of Liver Function, Histologic Features, and Differences Between the Sub-cohorts






(n ! 17) P value
Male gender 162 (53.3) 87 (56.5) 69 (51.9) 6 (35.3) .82
Age, y (range) 54 (17–77) 56 (17–77) 53 (21–75) 61 (33–74) <.05
BMI (kg/m2) 33.3 (30.0, 37.5) 35 (31.6, 38.7) 31.9 (28.7, 36.3) 31.2 (27.3, 37.0) <.001
Obesity 228 (75.0) 133 (86.4) 85 (63.9) 10 (58.8) <.001
Diabetes type 2 156 (51.3) 95 (61.7) 52 (39.1) 9 (52.9) <.01
Hypertension 203 (66.8) 87 (56.5) 102 (76.7) 14 (82.4) <.001
Hyperlipidemia 177 (58.2) 88 (57.1) 83 (62.4) 6 (35.3) .07
ALT 73 (48, 110) 73 (48, 109) 81 (51 110) 33 (24, 61) <.01
AST 50 (36, 69) 50 (38, 71) 51 (37, 68) 29 (24, 54) <.01
g-GT 84 (56, 162) 92 (59, 164) 80 (53, 161) 82 (45, 223) .5
Albumin 43 (40, 45) 44 (43, 47) 41 (39, 43) 45 (43, 47) <.001
Platelet count 233 (183, 283) 240 (190, 296) 226 (183, 270) 190 (176, 228) .05
Ferritin 154 (79, 313) 130 (68, 255) 220 (117, 357) 97 (51, 155) <.001
HbA1c 6.1 (5.5, 7.1) 6.3 (5.75, 7.6) 5.7 (5.3, 6.3) 6.5 (6.2, 7.4) <.001
Histologic !ndings
NASH 210 (69.1) 109 (70.8) 89 (66.9) 12 (70.6) .77
Steatosis 1/2/3 100/152/44 34/79/34 58/67/7 8/6/3 <.001
Ballooning 0/1/2 82/163/51 44/72/31 34/81/17 4/10/3 .26
Lobular in"ammation 0/1/2/3 63/162/68/3 27/68/49/2 32/87/12/1 4/7/6/0 <.001
Fibrosis 0/1/2/3/4 36/74/67/82/45 29/29/28/40/28 5/43/36/37/12 2/2/3/5/5 <.001
NOTE. Data are expressed as number (percentage) or median (25th, 75th percentiles). Histologic !ndings were scored according to the criteria proposed by
Kleiner et al.4 Comparisons between cohorts were carried out using the c2 or Kruskall-Wallis test. ALT (normal range, <50 U/L), AST (normal range, 5–35 U/L), g-
GT (normal range, 12-64 U/L), Albumin (normal range, 34–48 g/L), Platelet count (normal range, 150-450/nL), Ferritin (normal range, 20–275 ng/mL), HbA1c (normal
range, 4.1%–5.6%), obesity is de!ned as BMI >30 kg/m2. Boldface indicates statistical signi!cance.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; g-GT, gamma-glutamyl transferase; HbA1c, glycosylated hemoglobin;
NASH, nonalcoholic steatohepatitis; UK, United Kingdom.








(n ! 142) P value
CLDQ overall score 4.99 ("1.2) 5.31 ("1.1) 4.62 ("1.3) <.001
Abdominal symptoms 5.33 ("1.6) 5.69 ("1.4) 4.92 ("1.7) <.001
Fatigue 4.31 ("1.6) 4.61 ("1.5) 3.96 ("1.5) <.001
Systemic symptoms 5.09 ("1.3) 5.43 ("1.2) 4.71 ("1.3) <.001
Activity 5.43 ("1.4) 5.79 ("1.3) 5.02 ("1.4) <.001
Emotional functioning 4.93 ("1.5) 5.27 ("1.4) 4.54 ("1.5) <.001
Worry 5.18 ("1.5) 5.45 ("1.3) 4.86 ("1.6) <.01
NOTE. Data are expressed as means and standard deviations. Comparisons
between groups were carried out using the Mann-Whitney U test. Boldface
indicates statistical signi!cance.
CLDQ, Chronic Liver Disease Questionnaire.











P < .05) and severe lobular in!ammation (grade 3 vs 0,
3.9 [!1.8] vs 5.3 [!1.2]; P < .001), all with a difference
of >0.5 points, were associated with lower HRQL.
Advanced "brosis and compensated cirrhosis (F3/F4)
were observed in 127 patients (41.8%), and these
exhibited a trend toward lower HRQL (F3-4 vs F0-2, 4.9
[!1.2] vs 5.1 [!1.3]; P " .07). In contrast to the histo-
logic features of steatohepatitis, this was not statistically
signi"cant or clinically meaningful. Figure 1 summarizes
the histologic features and the associated CLDQ overall
scores. On multivariate analysis, correcting for country,
gender, age, BMI, and type 2 diabetes, an independent
association between impaired HRQL and hepatic
in!ammation (P < .05) but not "brosis (P " .47) was
detected. Also, gender (P < .0001), age (P < .05), BMI
(P < .001), and type 2 diabetes (P < .01) were inde-
pendently associated with impaired HRQL
(Supplementary Table 2).
Discussion
The current study explored HRQL in patients with
biopsy proven NAFLD from 3 European centers. HRQL is
an important facet when assessing the burden of a
chronic disease. Despite the lack of speci"c symptoms in
liver disease, patients can experience impairment in the
quality of life at an individual level.27 In patients with
NAFLD and other chronic liver disease, fatigue and
impaired sleeping quality are the most frequently re-
ported "ndings.12,27,28 Likewise, the number of comor-
bidities and medications are negatively correlated with
HRQL in patients with chronic liver disease.18 The
striking "nding of the current analysis in this well-
characterized European cohort was that, in contrast to
the published data on predictors of overall and liver-
speci"c mortality, lobular in!ammation correlated inde-
pendently with HRQL.6,29 These results differ from the
NASH CRN cohort, which found lower HRQL using the
generic short form-36 (SF-36) in NASH compared with a
healthy U.S. population and a signi"cant effect in
cirrhosis only.13 The apparent divergence of "brosis on
mortality and HRQL is intriguing and potentially re!ects
differences in the underlying mechanisms that contribute
to progression of the respective histologic lesion and the
loss in HRQL. Metabolic in!ammation creates a milieu in
which liver cell injury and "brogenesis occur and drive
disease progression over years. Various studies have
identi"ed hepatic "brosis but not in!ammation or stea-
tosis on liver biopsy as the histologic feature that cor-
relates best with overall and liver-related mortality.6,29
Although in!ammation and steatosis are prerequisites
for the diagnosis and disease progression, these features
are more dynamic compared with hepatic "brosis. On the
other hand, hepatic "brosis re!ects an aggregate of liver
injury that builds up over time and can be detected on
liver biopsy despite sampling variability. Nonetheless,
the disease activity, namely in!ammation and ballooning,
has been linked to elevated cytokine levels and markers
of systemic in!ammation.30 These in!ammatory markers
and metabolic stress are known to negatively affect the
mood and promote depressive symptoms.31
Data from clinical trials in chronic HCV or hepatitis B
virus infection support a dominant role of in!ammation
on HRQL. Viral elimination or suppression after antiviral
therapy was associated with improved HRQL, which ar-
gues for an effect of in!ammation on PROs, whereas
improvement of "brosis did not affect HRQL.20,26,32 Also,
improvement of HRQL was comparable in patients with
Table 3. CLDQ in Relation to Presence or Absence of Patient









Age #54 y 4.94 (!1.2) 5.05 (!1.3) .37
Obesity (BMI
>30 kg/m2)
4.83 (!1.2) 5.46 (!1.1) <.001
Diabetes type 2 4.74 (!1.2) 5.25 (!1.2) <.001
Hypertension 4.97 (!1.2) 5.04 (!1.3) .51
Hyperlipidemia 4.84 (!1.2) 5.24 (!1.2) <.01
Correlation coef!cient





Platelet count –0.12 .05
Ferritin 0.17 <.01
HbA1c –0.26 <.001
NOTE. Data presented as means and standard deviations. Obesity is de!ned
as BMI >30 kg/m2. Statistical dependence between parameters of metabolic
syndrome and CLDQ was measured by Mann-Whitney U test; to compare
laboratory levels and CLDQ score, Spearman’s rank correlation coef!cient was
performed. Boldface indicates statistical signi!cance.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CLDQ,
Chronic Liver Disease Questionnaire; g-GT, g-glutamyl transferase; HbA1c,
glycosylated hemoglobin.








(n " 210) P value
CLDQ overall score 4.99 (!1.2) 5.31 (!1.1) 4.85 (!1.3) <.01
Abdominal symptoms 5.33 (!1.6) 5.64 (!1.3) 5.19 (!1.7) .088
Fatigue 4.31 (!1.6) 4.76 (!1.5) 4.10 (!1.6) <.01
Systemic symptoms 5.09 (!1.3) 5.45 (!1.2) 4.93 (!1.4) <.01
Activity 5.43 (!1.4) 5.74 (!1.3) 5.29 (!1.4) <.01
Emotional functioning 4.93 (!1.5) 5.15 (!1.5) 4.83 (!1.5) .067
Worry 5.18 (!1.5) 5.47 (!1.5) 5.04 (!1.5) <.05
NOTE. Data are expressed as means and standard deviations. Comparisons
between groups were carried out using the Mann-Whitney U test. Boldface
indicates statistical signi!cance.
CLDQ, Chronic Liver Disease Questionnaire; NAFL, nonalcoholic fatty liver
disease; NASH, nonalcoholic steatohepatitis.











early and advanced !brosis after cure using direct-acting
antivirals.26 In a recent trial in patients with histologi-
cally con!rmed NASH and !brosis stage 2 or 3, an
improvement of !brosis by at least 1 stage resulted in an
improvement in HRQL.33 Beyond histologic !ndings, a
signi!cant negative impact of metabolic comorbidities,
including type 2 diabetes, obesity, or dyslipidemia, on
HRQL was observed. In line with the published data,
fatigue was the most frequently reported
symptom.12,27,34
The burden of disease for NAFLD is high, and an
exponential increase in Europe is predicted in the next
few years.35 In Germany, France, Italy, and UK there are
approximately 52 million people living with NAFLD, and
the connected annual costs have been estimated at 35
billion euros. These costs arise from liver-related
morbidity and associated comorbidities that amount to
spending in health care but also indirect cost related to
lost work productivity.36
The current analysis highlights the impact of lobular
in"ammation on HRQL, which to a lower extent trans-
lated into differences in HRQL between NAFL and NASH.
Currently, clinical trials are being conducted to assess
the resolution of steatohepatitis and improvement or
stabilization of hepatic !brosis as a primary endpoint.37
On the basis of the current analysis it can be expected
that improvement of steatohepatitis, and in particular
lobular in"ammation, will have measurable in"uence on
HRQL even independently of !brosis improvement.
Clinically meaningful differences were also detected with
regard to gender. Women scored lower in all sub-
categories of the CLDQ across all countries, indicating
that the burden of disease in women could be higher.
This effect was not explained by disease activity or
advanced stage. Interestingly, these !ndings are repli-
cated in studies on HCV and human immunode!ciency
virus co-infected patients that also showed signi!cantly
lower HRQL in women.19 Thus, it seems plausible that
Figure 1. Impact of histologic features of nonalcoholic fatty liver disease on health-related quality of life. (A) Steatosis,
(B) ballooning, (C) lobular in!ammation, (D) "brosis. CLDQ, Chronic Liver Disease Questionnaire.











CLDQ has a higher sensitivity to detect impairment in the
quality of life in women compared with men. Future
tools of HRQL will have to account for this gender-
speci!c difference.
The CLDQ assesses not only symptoms but also social
and emotional factors at a super!cial level by using 4–5
questions in the respective subsections. Therefore, it has
proven particularly feasible in an outpatient setting with
limited time resources. The CLDQ represents a disease-
speci!c tool with the capability to detect subtle
disease-speci!c aspects that are missed by more
commonly used generic tools. Nonetheless, the ability of
the CLDQ to differentiate subtler aspects can be ques-
tioned because most patients scored within a range of
2.5 points on this 7-point Likert scale, and further re-
!nements are now available.38 Beyond the assessment of
treatment response, HRQL could be potentially useful in
prioritizing patients for lifestyle interventions or phar-
macologic therapies in the future.
In summary, the current study highlights the link of
impaired HRQL with liver parenchymal in"ammation in
patients with NAFLD from Northern, Middle, and
Southern Europe. These !ndings contradict frequent
perception that patients with chronic liver disease are
asymptomatic. Our !ndings underline the need for an
appropriate tool to assess the symptoms that contribute
to the high disease burden in NASH. Because NAFLD is a
highly prevalent disease that causes a distinct loss in
HRQL and eventually also poses an economic burden, a
high priority should be placed on prevention and treat-
ment. With the emergence of medical therapy, the
improvement in HRQL will likely in"uence the choice of
drug in the future.
Supplementary Material
Note: To access the supplementary material accom-
panying this article, visit the online version of Clinical
Gastroenterology and Hepatology at www.cghjournal.org,
and at https://doi.org/10.1016/j.cgh.2018.12.016.
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Supplementary Table 1. Comparison of Health-Related Quality of Life in Sub-cohorts
Parameter Total (n ! 304) UK cohort (n ! 154) German cohort (n ! 133) Spanish cohort (n ! 17) P value
CLDQ overall score 4.99 ("1.2) 4.73 ("1.3) 5.27 ("1.1) 5.14 ("1.1) <.01
Abdominal symptoms 5.33 ("1.6) 5.24 ("1.6) 5.51 ("1.5) 4.76 ("1.6) .12
Fatigue 4.31 ("1.6) 4.12 ("1.6) 4.48 ("1.5) 4.64 ("1.7) .09
Systemic symptoms 5.09 ("1.3) 4.82 ("1.4) 5.37 ("1.2) 5.35 ("1.2) <.01
Activity 5.43 ("1.4) 5.21 ("1.5) 5.73 ("1.2) 5.12 ("1.4) <.01
Emotional functioning 4.93 ("1.5) 4.57 ("1.6) 5.30 ("1.3) 5.32 ("1.4) <.001
Worry 5.18 ("1.5) 4.91 ("1.7) 5.46 ("1.3) 5.38 ("1.1) <.01
NOTE. Data are expressed as means and standard deviations. Comparisons between cohorts were carried out using the Kruskal-Wallis test.
CLDQ, Chronic Liver Disease Questionnaire; UK, United Kingdom.
Supplementary Table 2. Associations Between Impaired
HRQL and Different Parameters
From Analysis of Covariance
Parameter DF











NOTE. Analysis of covariance after correction for confounders including
country, gender, age, BMI, and type 2 diabetes.
BMI, body mass index; DF, degrees of freedom.
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• Plasma PRO-C3 levels correlate with severity of stea-
tohepatitis and fibrosis stage.
• FIBC3 panel achieves good sensitivity and specificity
for the identification of F!3 fibrosis in NAFLD.
• FIBC3 panel uses a single threshold value, eliminat-
ing indeterminate results and outperforming other
non-invasive tools.
• A simplified version (ABC3D) is readily amenable to
use in clinical practice.
https://doi.org/10.1016/j.jhepr.2019.06.004
Lay summary
We performed a comprehensive, independent evalua-
tion of a collagen biomarker (PRO-C3) to detect and
quantify liver !brosis in patients with non-alcoholic
fatty liver disease (NAFLD). We report the develop-
ment of 2 diagnostic panels using PRO-C3 to identify
patients with advanced !brosis, one optimal but more
complex to calculate (FIBC3), the other easier to use







stepwisemultiple logistic regression analysis to identify indepen-
dent factors associated with fibrosis. Variables with p <0.05 by
multivariate analysis were used to construct scoring systems
(FIBC3 and ABC3D) to predict advanced fibrosis. Optimal cut-offs
for each component of ABC3D were selected using the Youden
index (J-Index) which attributes equal value to sensitivity and
specify. Cross-validation was performed using the leave-one-out
method to facilitate the calculation of over-fit bias reduced
estimates. We calculated reduced bias estimates of predicted
probability. This involved removing each individual subject and
re-estimating the model parameters and then classifying the sub-
ject based on the newparameters. This enabled us to interrogate a
suspicious positive or negative validation subject.
The diagnostic accuracies of both scoring systems were
determined by calculating the area under the receiver operating
characteristic curve (AUROC, the c-statistic) and its 95% CIs. The
5-point fibrosis scales presented both spectrum effect and ordinal
scale issues. To overcome this, we calculated the Obuchowski
measure using the package “nonbinROC” version 1.0.1 (https://
CRAN.R-project.org/package=nonbinROC) using the R statistical
analysis software platform.38 This is a measure of the probability
that our fibrosis index will correctly rank 2 randomly chosen
patient samples from different fibrosis stages according to
the weighting scheme, with a penalty score of 1 for incorrect
scoring.39 The method of DeLong, DeLong and Clarke-Pearson
was used to compare AUROCs.40 Validation was performed in
(1) the validation dataset (n = 298) and (2) in the full dataset
(n = 449). Using the ROC curve for the final model, a cut-off
point was selected using the Youden index (J-Index). ROC curves
were also calculated for the established diagnostic scores, AAR,
FIB4, APRI, NFS, BARD and the recently described ADAPT
score.10,24,27–29 All statistical analyses were performed using
SPSS software version 24.0 (SPSS Inc, Chicago, USA), R and SAS
version 9.1 (SAS Institute Inc., Cary, NC, USA).
Results
Characteristics of patient population
Table 1 summarises the clinico-demographic details of the study
population. The 449 patients were pooled from 7 international
centres (Table S1). No country of origin/centre effect was
detected in the analysis (p = 1.000).
Table 1. Baseline demographic and clinical characteristics of participants.^
Variable All patients
(n = 449)
Discovery cohort (n = 151) Validation group (n = 298) p value
Age (years) 52 ± 13 51.6 ± 13 51.5 ± 13 0.957
Gender (male) 263 (59%) 94 (62%) 169 (57%) 0.260
BMI (Kg/m2) 32.6 ± 6.8 32.9 ± 7.1 32.4 ± 6.4 0.608
T2DM 216 (48%) 74 (49%) 142 (48%) 0.786
ALT (U/L) 69 ± 41 66 ± 39 71 ± 42 0.166
High ALT (>40 U/L) 340 (76%) 112 (74%) 228 (77%) 0.585
AST (U/L) 47 ± 26 47 ± 26 48 ± 26 0.339
Albumin (g/dl) 44 ± 5 44 ± 4 44 ± 5 0.780
Platelets (X109/L) 230 ± 72 225 ± 61 233 ± 77 0.448
Cholesterol (mg/dl) 7 ± 14 7 ± 10 7.1 ± 16 0.630
Triglycerides (mg/dl) 3.8 ± 17 3.6 ± 16 3.9 ± 18 0.758
Collagen PRO–C3 (ng/ml) 18.9 ± 15 18.1 ± 14 19.3 ± 15 0.438
Collagen PRO–C6 (ng/ml) 9.6 ± 4.4 9.3 ± 4 9.8 ± 4.7 0.501
PRO–C4 (ng/ml) 266 ± 142 253 ± 147 273 ± 139 0.067
C4M (ng/ml) 27.3 ± 10 26.8 ± 10.1 27.6 ± 9.8 0.374
C3M (ng/ml) 11.6 ± 4 11.6 ± 4.8 11.6 ± 4.2 0.644
Fibrosis Stage (0/1/2/3/4) 90/100/92/101/66 36/28/27/34/26 54/72/65/67/40 0.309
Steatosis (0/1/2/3) 10/149/171/110 6/50/56/35 4/99/115/75 0.342
Ballooning (0/1/2) 112/188/138 38/60/49 74/128/89 0.791
Lobular Inflammation (0/1/2/3) 48/219/147/24 18/78/43/8 30/141/104/16 0.578
NAS 4 ± 2 4 ± 2 4 ± 2 0.848
FIB4 1.53 ± 1.07 1.55 ± 1.08 1.52 ± 1.06 0.483
AAR 0.76 ± 0.31 0.79 ± 0.34 0.75 ± 0.30 0.428
NAFLD Fibrosis Score –1.304 ± 1.796 –1.182 ± 1.797 –1.367 ± 1.795 0.303
APRI 0.68 ± 0.48 0.68 ± 0.51 0.68 ± 0.46 0.718
ADAPT Score 6.3 ± 2.2 6.3 ± 2.3 6.4 ± 2.2 0.652
BARD Score 2 ± 1 2 ± 1 2 ± 1 0.428
Centrally reviewed biopsies 254 (57%) 79 (52%) 175 (59%) 0.622
Mann-Whitney/ t tests were used to test for significant differences within continuous variables and Chi-Square test was used for categorical variables.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; T2DM, type 2 diabetes mellitus.
^The table shows the mean ± SD for continuous variables, number (%) for binary variables, and number per group for categorical variables.
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features on biopsy. The current study addresses the performance
of the PRO-C3 biomarker within the FDA BEST (Biomarkers,
EndpointS and other Tools) defined diagnostic context of use.11
Blood-based non-invasive tests for fibrosis can be dichotomised
into “indirect makers”, including simple non-invasive fibrosis
scores derived from clinical and biochemical indices, such as the
fibrosis-4 (FIB4) score and the NAFLD fibrosis score (NFS),12–16
and “direct biomarkers” thatmeasure collagen deposition ormatrix
turnover.17,18 Themajority of non-invasive tests exhibit high nega-
tive predictive value, implying that they are best employed to
exclude patients without advanced fibrosis (Kleiner !F2). However,
many issues existwith currently available biomarkers. For example,
FIB4 and NFS provide “indeterminate” results in a quarter of
patients19 and although elastography based techniques such as
Fibroscan™ (vibration controlled transient elastography [VCTE])
have a competitive diagnostic accuracy, they require specialist
equipment, are operator dependent and exhibit low success rates
in obese patients.20 Magnetic resonance elastography can accu-
rately diagnose fibrosis in patients with NAFLD.21,22 However, it is
expensive and not widely available in most centres. A mandate
therefore exists for improved biomarkers.
Research exploiting knowledge of collagen structure and
protease-protein interactions have resulted in the design of a spe-
cific ELISA that measures ADAMS2 mediated collagen cleavage
during the formation of type III collagen in fibrogenesis.23,24 Pre-
vious studies have shown that measuring formation of type III
collagen neo-epitopes (PRO-C3) as a single diagnostic marker or
by incorporation into a diagnostic panel can provide a reasonably
accurate assessment of disease stage and activity, but to date the
diagnostic panels require complex mathematical calculations
necessitating the use of an online App.25–30 Similarly, NFS and
FIB4 require the use of online calculators to generate a result.
This may be onerous in a busy clinical environment, limiting
adoption in the primary care setting.31,32 A simplified but accurate
fibrosis assessment algorithm would therefore help physicians to
risk stratify patients without recourse to an online calculator.
In the current study, we seek to: i) assess the performance of
PRO-C3 as a NASH-fibrosis biomarker within the BEST diagnostic
context of use; ii) develop and validate a novel biomarker panel
incorporating PRO-C3 and determine its performance in compari-
son to established clinical scores and previously reported biomar-
ker panels; and iii) develop and validate a simplified clinical tool
that is both accurate and clinically accessible immediately.
Materials and methods
Study design and participants
Fig. 1 shows the flow of patients through the study. Participants
were recruited at 7 specialist European centres. Patients eligible
for inclusion were "18 years, with suspected NAFLD undergoing a
diagnostic liver biopsy on clinical grounds. Patients were excluded
if they had evidence of coexistent liver disease or consumed greater
than 30 g of alcohol per day for males or greater than 20 g per day
for females. The human biological samples were sourced ethically
following receipt of informed consent from each patient and their
research usewas in accordancewith the terms of the informed con-
sents under an IRB/EC approved protocol at participating centres.
Clinical and laboratory assessments
Gender, age and body mass index (BMI; weight (kg)/height (m2))
were recorded for all patients at time of index liver biopsy. Patients
were classified as having type 2 diabetesmellitus (T2DM) if HbA1c
was >6.5% or theywere receiving dietary, oral hypoglycaemic drug
or insulin treatment for T2DM. Blood tests taken at the time of liver
biopsy were used to calculate the simple non-invasive scores. The
FIB4 score, APRI (aspartate aminotransferase to platelet ratio
index), NFS, ADAPT (Age, Diabetes, PRO-C3 and platelets panel)
score and BARD (BMI, aspartate aminotransferase to alanine
aminotransferase ratio [AAR], T2DM) score were calculated and
applied as previously described.13,29,33–35 PRO-C3 and additional
biomarkers PRO-C6, PRO-C4, C4M were assessed using competi-
tive ELISAs (Nordic Bioscience A/S, Denmark) measured by ex-
perienced technicians unaware of any associated clinical data.23,36
Histological assessment
Liver biopsies were performed at each centre as per unit protocol.
Target biopsy length was "15 mm. Biopsies were stained with
haematoxylin and eosin andMasson's trichrome.Histological diag-
nosis, grade of steatosis and scoring for NAFLD activity and fibrosis
stage were performed by expert liver pathologists at each study
site according to the NASH Clinical Research Network (CRN) classi-
fication.37 To reduce the element of inter-observer variability, over
half of all biopsies (254, 57%) in our study were centrally reviewed
by an expert member of the Elucidating Pathways of Steatohepati-
tis (EPoS)HistopathologyGroup (DT). Aweighted kappa coefficient
of 0.90 for fibrosis stage was established, demonstrating a very
high level of inter-observer agreement.
Statistical analysis
The primary endpoint of the study was to predict the presence of
advanced fibrosis (stages 3–4). The combined cohort of 449patients
was randomly separated into approximately 1/3 (n = 151) (dis-
covery cohort) and 2/3 (n = 298) of patients (validation cohort)
for model building and validation. Continuous variables were
compared using the t test and categorical variables using Fisher’s
exact test. The Kruskal-Wallis test was used to perform compari-
sons between mean marker levels followed by Dunn’s multiple
comparison tests. In the discovery cohort, significant variables
on univariate analysis (p <0.05) were included in the backward
682 Patients undergoing liver biopsy
64 patients excluded
>12 months between liver biopsy
and PROC3 sample collection
169 patients excluded
Incomplete clinical data
449 Patients eligible for inclusion









Fig. 1. Patient flow for analysis inclusion.










stepwisemultiple logistic regression analysis to identify indepen-
dent factors associated with fibrosis. Variables with p <0.05 by
multivariate analysis were used to construct scoring systems
(FIBC3 and ABC3D) to predict advanced fibrosis. Optimal cut-offs
for each component of ABC3D were selected using the Youden
index (J-Index) which attributes equal value to sensitivity and
specify. Cross-validation was performed using the leave-one-out
method to facilitate the calculation of over-fit bias reduced
estimates. We calculated reduced bias estimates of predicted
probability. This involved removing each individual subject and
re-estimating the model parameters and then classifying the sub-
ject based on the newparameters. This enabled us to interrogate a
suspicious positive or negative validation subject.
The diagnostic accuracies of both scoring systems were
determined by calculating the area under the receiver operating
characteristic curve (AUROC, the c-statistic) and its 95% CIs. The
5-point fibrosis scales presented both spectrum effect and ordinal
scale issues. To overcome this, we calculated the Obuchowski
measure using the package “nonbinROC” version 1.0.1 (https://
CRAN.R-project.org/package=nonbinROC) using the R statistical
analysis software platform.38 This is a measure of the probability
that our fibrosis index will correctly rank 2 randomly chosen
patient samples from different fibrosis stages according to
the weighting scheme, with a penalty score of 1 for incorrect
scoring.39 The method of DeLong, DeLong and Clarke-Pearson
was used to compare AUROCs.40 Validation was performed in
(1) the validation dataset (n = 298) and (2) in the full dataset
(n = 449). Using the ROC curve for the final model, a cut-off
point was selected using the Youden index (J-Index). ROC curves
were also calculated for the established diagnostic scores, AAR,
FIB4, APRI, NFS, BARD and the recently described ADAPT
score.10,24,27–29 All statistical analyses were performed using
SPSS software version 24.0 (SPSS Inc, Chicago, USA), R and SAS
version 9.1 (SAS Institute Inc., Cary, NC, USA).
Results
Characteristics of patient population
Table 1 summarises the clinico-demographic details of the study
population. The 449 patients were pooled from 7 international
centres (Table S1). No country of origin/centre effect was
detected in the analysis (p = 1.000).
Table 1. Baseline demographic and clinical characteristics of participants.^
Variable All patients
(n = 449)
Discovery cohort (n = 151) Validation group (n = 298) p value
Age (years) 52 ± 13 51.6 ± 13 51.5 ± 13 0.957
Gender (male) 263 (59%) 94 (62%) 169 (57%) 0.260
BMI (Kg/m2) 32.6 ± 6.8 32.9 ± 7.1 32.4 ± 6.4 0.608
T2DM 216 (48%) 74 (49%) 142 (48%) 0.786
ALT (U/L) 69 ± 41 66 ± 39 71 ± 42 0.166
High ALT (>40 U/L) 340 (76%) 112 (74%) 228 (77%) 0.585
AST (U/L) 47 ± 26 47 ± 26 48 ± 26 0.339
Albumin (g/dl) 44 ± 5 44 ± 4 44 ± 5 0.780
Platelets (X109/L) 230 ± 72 225 ± 61 233 ± 77 0.448
Cholesterol (mg/dl) 7 ± 14 7 ± 10 7.1 ± 16 0.630
Triglycerides (mg/dl) 3.8 ± 17 3.6 ± 16 3.9 ± 18 0.758
Collagen PRO–C3 (ng/ml) 18.9 ± 15 18.1 ± 14 19.3 ± 15 0.438
Collagen PRO–C6 (ng/ml) 9.6 ± 4.4 9.3 ± 4 9.8 ± 4.7 0.501
PRO–C4 (ng/ml) 266 ± 142 253 ± 147 273 ± 139 0.067
C4M (ng/ml) 27.3 ± 10 26.8 ± 10.1 27.6 ± 9.8 0.374
C3M (ng/ml) 11.6 ± 4 11.6 ± 4.8 11.6 ± 4.2 0.644
Fibrosis Stage (0/1/2/3/4) 90/100/92/101/66 36/28/27/34/26 54/72/65/67/40 0.309
Steatosis (0/1/2/3) 10/149/171/110 6/50/56/35 4/99/115/75 0.342
Ballooning (0/1/2) 112/188/138 38/60/49 74/128/89 0.791
Lobular Inflammation (0/1/2/3) 48/219/147/24 18/78/43/8 30/141/104/16 0.578
NAS 4 ± 2 4 ± 2 4 ± 2 0.848
FIB4 1.53 ± 1.07 1.55 ± 1.08 1.52 ± 1.06 0.483
AAR 0.76 ± 0.31 0.79 ± 0.34 0.75 ± 0.30 0.428
NAFLD Fibrosis Score –1.304 ± 1.796 –1.182 ± 1.797 –1.367 ± 1.795 0.303
APRI 0.68 ± 0.48 0.68 ± 0.51 0.68 ± 0.46 0.718
ADAPT Score 6.3 ± 2.2 6.3 ± 2.3 6.4 ± 2.2 0.652
BARD Score 2 ± 1 2 ± 1 2 ± 1 0.428
Centrally reviewed biopsies 254 (57%) 79 (52%) 175 (59%) 0.622
Mann-Whitney/ t tests were used to test for significant differences within continuous variables and Chi-Square test was used for categorical variables.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; T2DM, type 2 diabetes mellitus.
^The table shows the mean ± SD for continuous variables, number (%) for binary variables, and number per group for categorical variables.
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(FIBC3 and ABC3D) to predict advanced fibrosis. Optimal cut-offs
for each component of ABC3D were selected using the Youden
index (J-Index) which attributes equal value to sensitivity and
specify. Cross-validation was performed using the leave-one-out
method to facilitate the calculation of over-fit bias reduced
estimates. We calculated reduced bias estimates of predicted
probability. This involved removing each individual subject and
re-estimating the model parameters and then classifying the sub-
ject based on the newparameters. This enabled us to interrogate a
suspicious positive or negative validation subject.
The diagnostic accuracies of both scoring systems were
determined by calculating the area under the receiver operating
characteristic curve (AUROC, the c-statistic) and its 95% CIs. The
5-point fibrosis scales presented both spectrum effect and ordinal
scale issues. To overcome this, we calculated the Obuchowski
measure using the package “nonbinROC” version 1.0.1 (https://
CRAN.R-project.org/package=nonbinROC) using the R statistical
analysis software platform.38 This is a measure of the probability
that our fibrosis index will correctly rank 2 randomly chosen
patient samples from different fibrosis stages according to
the weighting scheme, with a penalty score of 1 for incorrect
scoring.39 The method of DeLong, DeLong and Clarke-Pearson
was used to compare AUROCs.40 Validation was performed in
(1) the validation dataset (n = 298) and (2) in the full dataset
(n = 449). Using the ROC curve for the final model, a cut-off
point was selected using the Youden index (J-Index). ROC curves
were also calculated for the established diagnostic scores, AAR,
FIB4, APRI, NFS, BARD and the recently described ADAPT
score.10,24,27–29 All statistical analyses were performed using
SPSS software version 24.0 (SPSS Inc, Chicago, USA), R and SAS
version 9.1 (SAS Institute Inc., Cary, NC, USA).
Results
Characteristics of patient population
Table 1 summarises the clinico-demographic details of the study
population. The 449 patients were pooled from 7 international
centres (Table S1). No country of origin/centre effect was
detected in the analysis (p = 1.000).
Table 1. Baseline demographic and clinical characteristics of participants.^
Variable All patients
(n = 449)
Discovery cohort (n = 151) Validation group (n = 298) p value
Age (years) 52 ± 13 51.6 ± 13 51.5 ± 13 0.957
Gender (male) 263 (59%) 94 (62%) 169 (57%) 0.260
BMI (Kg/m2) 32.6 ± 6.8 32.9 ± 7.1 32.4 ± 6.4 0.608
T2DM 216 (48%) 74 (49%) 142 (48%) 0.786
ALT (U/L) 69 ± 41 66 ± 39 71 ± 42 0.166
High ALT (>40 U/L) 340 (76%) 112 (74%) 228 (77%) 0.585
AST (U/L) 47 ± 26 47 ± 26 48 ± 26 0.339
Albumin (g/dl) 44 ± 5 44 ± 4 44 ± 5 0.780
Platelets (X109/L) 230 ± 72 225 ± 61 233 ± 77 0.448
Cholesterol (mg/dl) 7 ± 14 7 ± 10 7.1 ± 16 0.630
Triglycerides (mg/dl) 3.8 ± 17 3.6 ± 16 3.9 ± 18 0.758
Collagen PRO–C3 (ng/ml) 18.9 ± 15 18.1 ± 14 19.3 ± 15 0.438
Collagen PRO–C6 (ng/ml) 9.6 ± 4.4 9.3 ± 4 9.8 ± 4.7 0.501
PRO–C4 (ng/ml) 266 ± 142 253 ± 147 273 ± 139 0.067
C4M (ng/ml) 27.3 ± 10 26.8 ± 10.1 27.6 ± 9.8 0.374
C3M (ng/ml) 11.6 ± 4 11.6 ± 4.8 11.6 ± 4.2 0.644
Fibrosis Stage (0/1/2/3/4) 90/100/92/101/66 36/28/27/34/26 54/72/65/67/40 0.309
Steatosis (0/1/2/3) 10/149/171/110 6/50/56/35 4/99/115/75 0.342
Ballooning (0/1/2) 112/188/138 38/60/49 74/128/89 0.791
Lobular Inflammation (0/1/2/3) 48/219/147/24 18/78/43/8 30/141/104/16 0.578
NAS 4 ± 2 4 ± 2 4 ± 2 0.848
FIB4 1.53 ± 1.07 1.55 ± 1.08 1.52 ± 1.06 0.483
AAR 0.76 ± 0.31 0.79 ± 0.34 0.75 ± 0.30 0.428
NAFLD Fibrosis Score –1.304 ± 1.796 –1.182 ± 1.797 –1.367 ± 1.795 0.303
APRI 0.68 ± 0.48 0.68 ± 0.51 0.68 ± 0.46 0.718
ADAPT Score 6.3 ± 2.2 6.3 ± 2.3 6.4 ± 2.2 0.652
BARD Score 2 ± 1 2 ± 1 2 ± 1 0.428
Centrally reviewed biopsies 254 (57%) 79 (52%) 175 (59%) 0.622
Mann-Whitney/ t tests were used to test for significant differences within continuous variables and Chi-Square test was used for categorical variables.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; T2DM, type 2 diabetes mellitus.
^The table shows the mean ± SD for continuous variables, number (%) for binary variables, and number per group for categorical variables.
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stepwisemultiple logistic regression analysis to identify indepen-
dent factors associated with fibrosis. Variables with p <0.05 by
multivariate analysis were used to construct scoring systems
(FIBC3 and ABC3D) to predict advanced fibrosis. Optimal cut-offs
for each component of ABC3D were selected using the Youden
index (J-Index) which attributes equal value to sensitivity and
specify. Cross-validation was performed using the leave-one-out
method to facilitate the calculation of over-fit bias reduced
estimates. We calculated reduced bias estimates of predicted
probability. This involved removing each individual subject and
re-estimating the model parameters and then classifying the sub-
ject based on the newparameters. This enabled us to interrogate a
suspicious positive or negative validation subject.
The diagnostic accuracies of both scoring systems were
determined by calculating the area under the receiver operating
characteristic curve (AUROC, the c-statistic) and its 95% CIs. The
5-point fibrosis scales presented both spectrum effect and ordinal
scale issues. To overcome this, we calculated the Obuchowski
measure using the package “nonbinROC” version 1.0.1 (https://
CRAN.R-project.org/package=nonbinROC) using the R statistical
analysis software platform.38 This is a measure of the probability
that our fibrosis index will correctly rank 2 randomly chosen
patient samples from different fibrosis stages according to
the weighting scheme, with a penalty score of 1 for incorrect
scoring.39 The method of DeLong, DeLong and Clarke-Pearson
was used to compare AUROCs.40 Validation was performed in
(1) the validation dataset (n = 298) and (2) in the full dataset
(n = 449). Using the ROC curve for the final model, a cut-off
point was selected using the Youden index (J-Index). ROC curves
were also calculated for the established diagnostic scores, AAR,
FIB4, APRI, NFS, BARD and the recently described ADAPT
score.10,24,27–29 All statistical analyses were performed using
SPSS software version 24.0 (SPSS Inc, Chicago, USA), R and SAS
version 9.1 (SAS Institute Inc., Cary, NC, USA).
Results
Characteristics of patient population
Table 1 summarises the clinico-demographic details of the study
population. The 449 patients were pooled from 7 international
centres (Table S1). No country of origin/centre effect was
detected in the analysis (p = 1.000).
Table 1. Baseline demographic and clinical characteristics of participants.^
Variable All patients
(n = 449)
Discovery cohort (n = 151) Validation group (n = 298) p value
Age (years) 52 ± 13 51.6 ± 13 51.5 ± 13 0.957
Gender (male) 263 (59%) 94 (62%) 169 (57%) 0.260
BMI (Kg/m2) 32.6 ± 6.8 32.9 ± 7.1 32.4 ± 6.4 0.608
T2DM 216 (48%) 74 (49%) 142 (48%) 0.786
ALT (U/L) 69 ± 41 66 ± 39 71 ± 42 0.166
High ALT (>40 U/L) 340 (76%) 112 (74%) 228 (77%) 0.585
AST (U/L) 47 ± 26 47 ± 26 48 ± 26 0.339
Albumin (g/dl) 44 ± 5 44 ± 4 44 ± 5 0.780
Platelets (X109/L) 230 ± 72 225 ± 61 233 ± 77 0.448
Cholesterol (mg/dl) 7 ± 14 7 ± 10 7.1 ± 16 0.630
Triglycerides (mg/dl) 3.8 ± 17 3.6 ± 16 3.9 ± 18 0.758
Collagen PRO–C3 (ng/ml) 18.9 ± 15 18.1 ± 14 19.3 ± 15 0.438
Collagen PRO–C6 (ng/ml) 9.6 ± 4.4 9.3 ± 4 9.8 ± 4.7 0.501
PRO–C4 (ng/ml) 266 ± 142 253 ± 147 273 ± 139 0.067
C4M (ng/ml) 27.3 ± 10 26.8 ± 10.1 27.6 ± 9.8 0.374
C3M (ng/ml) 11.6 ± 4 11.6 ± 4.8 11.6 ± 4.2 0.644
Fibrosis Stage (0/1/2/3/4) 90/100/92/101/66 36/28/27/34/26 54/72/65/67/40 0.309
Steatosis (0/1/2/3) 10/149/171/110 6/50/56/35 4/99/115/75 0.342
Ballooning (0/1/2) 112/188/138 38/60/49 74/128/89 0.791
Lobular Inflammation (0/1/2/3) 48/219/147/24 18/78/43/8 30/141/104/16 0.578
NAS 4 ± 2 4 ± 2 4 ± 2 0.848
FIB4 1.53 ± 1.07 1.55 ± 1.08 1.52 ± 1.06 0.483
AAR 0.76 ± 0.31 0.79 ± 0.34 0.75 ± 0.30 0.428
NAFLD Fibrosis Score –1.304 ± 1.796 –1.182 ± 1.797 –1.367 ± 1.795 0.303
APRI 0.68 ± 0.48 0.68 ± 0.51 0.68 ± 0.46 0.718
ADAPT Score 6.3 ± 2.2 6.3 ± 2.3 6.4 ± 2.2 0.652
BARD Score 2 ± 1 2 ± 1 2 ± 1 0.428
Centrally reviewed biopsies 254 (57%) 79 (52%) 175 (59%) 0.622
Mann-Whitney/ t tests were used to test for significant differences within continuous variables and Chi-Square test was used for categorical variables.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; T2DM, type 2 diabetes mellitus.
^The table shows the mean ± SD for continuous variables, number (%) for binary variables, and number per group for categorical variables.
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for all 2-way interactions with no significant outcomes (p >0.05).
These 5 variables were incorporated into a model that distin-
guished advanced fibrosis (F3-4) from mild fibrosis (F0-F2). The
diagnostic panel “FIBC3” was calculated from the regression for-
mula for prediction of severity of fibrosis: -5.939 + (0.053*Age) +
(0.076*BMI) + (1.614*T2DM) – (0.009*platelets) + (0.071*PRO-C3).
FIBC3 correlated strongly with fibrosis stage (rho = 0.630,
p <0.0001), which remained significant independently of NAS. In
the discovery cohort, the AUROC for FIBC3 was 0.89 (95% CI
0.843–0.941, p <0.001).
To facilitate adoption in a clinical setting, a simplified score
based on the same 5 variables identified as significant on univariate
analysis andweighted according to their odds ratio (OR) valueswas
generated. The derived “ABC3D” score comprises:A =Age>50 years,
B = BMI>30, C = platelet Count<200, 3 = PRO-C3>15.5 ng/ml,
Diabetes = present. Optimal thresholds for each variable were
selected by maximising the Youden index for the corresponding
ROC curves. The presence of each factor scored 1 point, except
for T2DM which, with an OR of 5, was awarded 2 points to yield
a maximum score of 6. In the discovery cohort, the AUROC for
ABC3D was 0.88 (95% CI 0.822–0.929, p <0.001).
Validation of FIBC3 and ABC3Dmodel accuracy and derivation
of diagnostic thresholds for advanced !brosis
The diagnostic accuracy of these models for the detection of
advanced fibrosis was confirmed in a the validation cohort (n =
298) and also in the overall combined cohort (n = 449). Diagnostic
accuracy was assessed by the standard AUROC and also the
weighted AUROC computed using the Obuchowski measure to
account for spectrum effect and ordinal scale.
Table 3. Diagnostic accuracy of non-invasive tests by detecting Histologic stage F3–F4 and weighted AUROC derived from the Obuchowski measure.
Combined cohort (n = 449)
Non-invasive test AUROC 95% CI Adj
AUROC
SD 95% CI
AAR 0.67 0.615–0.716 0.62 0.019 0.581–0.653
APRI 0.75 0.698–0.794 0.68 0.017 0.652–0.717
BARD 0.71 0.664–0.761 0.67 0.017 0.642–0.707
FIB4 0.78 0.732–0.820 0.70 0.015 0.671–0.731
NFS 0.79 0.751–0.838 0.72 0.015 0.694–0.752
ADAPT 0.85 0.815–0.888 0.77 0.014 0.739–0.794
PRO–C3 0.76 0.718–0.811 0.69 0.017 0.660–0.726
FIB–C3 0.85 0.812–0.886 0.77 0.013 0.745–0.797
ABC3D 0.83 0.793–0.868 0.76 0.013 0.730–0.783
p value <0.0001
Discovery cohort (n = 151)
AAR 0.66 0.579–0.751 0.62 0.031 0.555–0.675
APRI 0.75 0.669–0.830 0.69 0.028 0.638–0.748
BARD 0.76 0.683–0.834 0.69 0.028 0.637–0.746
FIB4 0.80 0.726–0.867 0.70 0.026 0.651–0.751
NFS 0.85 0.791–0.911 0.71 0.023 0.669–0.758
ADAPT 0.86 0.800–0.917 0.74 0.025 0.695–0.793
PRO–C3 0.75 0.661–0.831 0.68 0.031 0.617–0.740
FIB–C3 0.89 0.843–0.941 0.75 0.021 0.707–0.789
ABC3D 0.88 0.822–0.929 0.75 0.022 0.704–0.790
p value <0.0001
Validation cohort (n = 298)
AAR 0.66 0.599–0.725 0.62 0.024 0.571–0.663
APRI 0.75 0.686–0.805 0.68 0.021 0.640–0.722
BARD 0.69 0.624–0.749 0.66 0.021 0.623–0.705
FIB4 0.76 0.707–0.819 0.70 0.019 0.644–0.739
NFS 0.76 0.701–0.818 0.73 0.019 0.692–0.766
ADAPT 0.85 0.803–0.896 0.78 0.017 0.749–0.815
PRO–C3 0.78 0.727–0.838 0.70 0.020 0.622–0.741
FIB–C3 0.83 0.777–0.880 0.79 0.017 0.753–0.819
ABC3D 0.81 0.755–0.856 0.76 0.017 0.730–0.795
p value <0.0001
*Prevalence advanced fibrosis *combined cohort = 0.37 *Discovery cohort = 0.40 * Validation cohort = 0.36
*DeLong DeLong Clarke test for comparison of AUROC
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PRO-C3 levels correlated with steatohepatitis and !brosis stage
Across all histological features (steatosis, lobular inflammation,
hepatocyte ballooning, fibrosis), PRO-C3 was positively asso-
ciated with increasing NAFLD severity (Fig. 2). In the discovery
cohort (n = 151), PRO-C3 correlated with the NAFLD activity
score (NAS) (rho = 0.304, p <0.0001) and fibrosis stage (rho =
0.422, p <0.0001). Confirming that PRO-C3 is primarily a fibrosis
marker, the correlation with fibrosis stage remained significant
when controlling for NAS however the converse did not hold
true. Indeed, PRO-C3 exhibited the strongest correlation with
fibrosis stage when compared to a number of other putative
extracellular matrix turnover biomarkers (PRO-C6 (rho = 0.355),
PRO-C4 (rho = 0.279), C4M (rho = 0.177), p <0.05).
In the discovery cohort (n = 151) an optimal PRO-C3 cut-off
level for the detection of advanced fibrosis was determined.
PRO-C3 >15.5 ng/ml had an AUROC of 0.73 for the detection of
advanced fibrosis !F3 (sensitivity 60%, specificity 74%, accuracy
68%). This was replicated in the validation cohort (n = 298)
(AUROC = 0.78, sensitivity 72%, specificity 71%, accuracy 71%)
(Table S2). The sensitivity and specificity for fibrosis across a
range of PRO-C3 thresholds are reported for the overall cohort
(Table S3).
Development of panels incorporating PRO-C3 that are
diagnostic for advanced !brosis
To identify other clinical factors that readily predict the presence of
fibrosis, additional analyses were conducted. Table 2 shows the
results of univariate and multivariate analyses preformed in the
discovery cohort. Using backward logistic regression, 5 variables
remained significantly associated with advanced fibrosis: age,
BMI, T2DM, platelets and PRO-C3. Nomulti-collinearitywas identi-
fied between variables used in the model. Variables were assessed
r
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Fig. 2. PRO-C3 and its association with non-alcoholic fatty liver disease severity (complete cohort n = 449). Spearman’s correlation coefficient rs measures the
strength and direction of association between 2 variables. Independent samples were compared using the Kruskal-Wallis test. All data are represented as medians,
with variation in expression shown in Tukey plots. P values <0.05 were considered significant.
Table 2. Variables Associated with the Presence of Advanced Fibrosis (stage F3-4) in the Discovery Cohort (n = 151).
Univariate Adjusted (Multivariate)
Variable Odds Ratio 95% CI p value Odds Ratio 95% CI p value
Age 1.088 1.049–1.128 <0.0001 1.055 1.008–1.103 0.022
Gender 1.172 0.599–2.291 0.643
BMI 1.090 1.035–1.148 0.001 1.079 1.014–1.148 0.017
T2DM 8.570 4.003–18.348 <0.0001 5.023 1.920–13.140 0.001
ALT 1.002 0.994–1.011 0.611
AST 1.020 1.005–1.034 0.007
Albumin 0.934 0.853–1.021 0.133
Platelets 0.986 0.986–0.979 <0.0001 0.991 0.982–1.000 0.039
Cholesterol 0.841 0.714–0.990 0.038
Triglycerides 1.024 0.952–1.101 0.520
PRO-C3 1.079 1.039–1.120 <0.0001 1.074 1.023–1.127 0.004
AST-ALT Ratio 3.072 1.119–8.436 0.029
FIBC3:
–5.939 + (0.053*Age) + (0.076*BMI) + (1.614*T2DM) – (0.009*platelets) + (0.071*PRO–C3)
ABC3D:
Age >50 = 1 point, BMI >30 = 1 point, platelet Count <200 = 1 point, PRO–C3 >15.5 = 1 point, Diabetes = 2 points
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; T2DM, type 2 diabetes mellitus.






For FIBC3, the AUROC remained high in both the validation
cohort (0.83, 95% CI 0.777-0.880) and the combined cohort (0.85,
95% CI 0.812-0.886). The weighted AUROC was calculated to be
0.77, 0.75 and 0.79 in the combined, discovery and validation
cohorts, respectively. Similar results were obtained for ABC3D
with AUROC of 0.81 and 0.83 in the validation and combined
cohorts, respectivelY (Table 3). Reduced bias estimates of predicted
probability were calculated in the discovery and validation cohorts,
employing the leave-one-out method of cross-validation as pre-
viously described. To assess the added value of including PRO-C3
in the diagnostic model, we removed PRO-C3 from the FIBC3
model. This yeildedAUROCs of (0.80, 0.86 and 0.76) in the total, dis-
covery and validation cohorts, respectively. These improved to
(0.85, 0.89 and 0.83) with the inclusion of PRO-C3 in the model.
An optimal FIBC3 threshold value of >-0.4 was chosen using
the Youden index (sensitivity 83%, specificity 80%, positive predic-
tive value [PPV] 74% and negative predictive value [NPV] 88%). An
optimal ABC3D cut-off level for the detection of advanced fibrosis
was >3. In the validation cohort (n = 298), FIBC3 exhibited a sensi-
tivity of 75%, specificity of 75%, accuracy of 75% (Table 4). In the
discovery cohort, ABC3D exhibited a sensitivity of 77%, specificity
of 82%, and accuracy of 80%. This was replicated in the validation
cohort, where a sensitivity of 66%, specificity of 75% and accuracy
of 73% were observed.
Both FIBC3 and ABC3D performance were superior to simple
non-invasive scores in common use, with accuracies of 75% and
73%, respectively. Performance characteristics of FIBC3 and the
simplified ABC3D score were comparable to the recently
described ADAPT score (Table 4). Comparing AUROCs using the
DeLong, DeLong and Clarke-Pearson method confirmed that
FIBC3 and ABC3D have similar performance characteristics (p =
0.1422) as do FIBC3 and ADAPT (p = 0.1859). Using the FIBC3
model, the optimal threshold correctly staged 224 out of 298
patients (75%) in the validation cohort, compared to 227 patients
(76%) with ADAPT and 217 (73%) with ABC3D. Considering NPV,
of 191 patients with mild fibrosis, 144 (75%) were staged cor-
rectly using FIBC3 or ABC3D, equal to ADAPT (75%) (Table 5). In
the combined cohort (n = 449), 347 of the patients (77%) were
correctly staged using FIBC3, which outperformed both FIB4 at
304 (68%) and ADAPT at 341 (76%). The most simple model,
ABC3D, had a diagnostic accuracy of 75% correctly classifying
338 cases into mild or severe fibrosis.
Table 4. Optimal cut-off values for the detection of advanced fibrosis (!F3) as per Youden index derived in discovery cohort (prevalence 0.40, n = 151) and
applied in validation cohort (prevalence 0.36, n = 298).




PPV (%) NPV (%) Accuracy (%)
FIB-C3 0.89 >–0.4 83 80 74 88 81
ABC3D 0.88 >3 77 82 74 84 80
Validation cohort
Cut-off Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%)
AAR >0.8 46 71 47 70 62
APRI >1.5 11 96 63 66 66
BARD >2 76 51 47 79 60
FIB4 >2.67 21 94 67 68 68
NFS >0.676 27 95 78 70 71
ADAPT >6.3 76 75 63 86 76
FIB–C3 >–0.4 75 75 62 84 75
ABC3D >3 66 75 61 80 73
PPV, positive predictive value; NPV, negative predictive value.
Table 5. Validation cohort divided into mild and severe fibrosis (prevalence 0.39, n = 298).
F0–2
‘Rule out’ advanced fibrosis
F3–4









N = 191 n/N (%) n/N (%) n/N (%) N = 107 n/N (%) n/N (%) n/N (%)
AAR <0.8 135/191 (71) 56/191 (29) AAR >0.8 49/107 (46) 58/107 (54)
APRI <0.5 112/191 (59) 72/191 (38) 7/191 (3) APRI >1.5 12/107 (11) 72/107 (67) 23/107 (22)
BARD <2 98/191 (51) 93/191 (49) BARD >2 81/107 (76) 26/107 (24)
FIB4 <1.3 133/191 (70) 47/191 (25) 8/188 (5) FIB4 >2.67 22/107 (20) 53/107 (50) 32/107 (30)
NFS <–1.433 120/191 (64) 63/191 (33) 5/191 (3) NFS >0.676 29/107 (27) 51/107 (48) 27/107 (25)
ADAPT <6.3 144/191 (75) 47/191 (25) ADAPT >6.3 83/107 (78) 24/107 (22)
FIBC3 <–0.4 144/191 (75) 47/191 (25) FIBC3 >–0.4 80/107 (75) 27/107 (25)
ABC3D <3 144/191 (75) 47/191 (25) ABC3D >3 73/107 (68) 34/107 (32)






Performance of FIBC3 and ABC3D in real-world settings
We assessed the performance of FIBC3 and ABC3D in a range of
pre-test probability scenarios that may be encountered across
primary care and specialist care environments, where the preva-
lence of advanced fibrosis varies, to see if they were equivalent.
The PPV and NPV were calculated across an advanced and mild
fibrosis prevalence range between 5–50% (Table 6). We also stra-
tified our validation cohort in different, clinically distinct, sub-
populations and observed that performance was maintained
across all sub-populations, with a reliable NPV for advanced
fibrosis >74% (Table S4,5).
Performance of PRO-C3, FIBC3 and ABC3D as pre-screening
tools prior to liver biopsy to support clinical trial recruitment
As there is also a need for tools to assist in pre-screening patients for
clinical trials in NASH, we modelled the performance of PRO-C3 as
pre-screening tools for entry into clinical trials of fibrosing steatohe-
patitis. Two target populations were modelled: (i) “tdNASH”,
defined as NAS !4 with at least 1 point each for steatosis, hepato-
cyte ballooning and hepatic inflammation and fibrosis stage !F2;
and (ii) “tdNASH-Cirrhosis”, defined as above but with fibrosis
stage F4. For tdNASH, a PRO-C3 level >14.5 ng/ml had an AUROC
of 0.68 (sensitivity 59%, specificity 69%, accuracy 64%). This was
replicated in the validation cohort (n = 298), AUROC = 0.76,
sensitivity 70%, specificity 68%, accuracy 69%. Similarly, a PRO-C3
level >16.5 ng/ml identified tdNASH-Cirrhosis with an AUROC of
0.68 (sensitivity 74%, specificity 67%, accuracy 68%). This was repli-
cated in the validation cohort (n = 298), AUROC = 0.76, sensitivity
76%, specificity 61%, accuracy 63% (Table S2). The results for the
FIBC3 and ABC3D scores in the complete cohort (n = 449) are
shown in Table S6. In general, tests incorporating PRO-C3 per-
formed well. The most accurate test for the detection of tdNASH
was FIBC3 >-0.4 (71%). Phase II/III clinical trials that are currently
recruiting will be informative for the further validation of these
findings.
ABC3D to improve the accuracy of NFS and FIB4 scores
Although FIB4 and NFS are useful, the use of 2 cut-off thresholds
leads to indeterminate results that fail to classify a substantial
proportion of patients. For each diagnostic test we employed a
method of sequential testing by applying the low and high cut-
off values. The residual cohort of patients with NAFLD and inde-
terminate scores were then assessed with the ABC3D diagnostic
algorithm to detect cases of advanced fibrosis (Tables S7,8).
With the application of sequential testing, the accuracy improved
from 52% to 70% in the cases involving indeterminate FIB4 scores
and from 54% to 77% in the case involving indeterminate NFS
scores.
Table 6. Predictive values of cut-offs at different prevalences of advanced and mild fibrosis.
Combined Cohort (n = 449)
Predictive values of cut-offs for different prevalences of advanced fibrosis (F>3); “Rule in” advanced fibrosis
FIBC3 >–0.4 ABC3D >3 FIB4 >2.67 NFS >0.676 ADAPT >6.3
Prevalence of significant fibrosis (%) PPV (%) NPV (%) PPV (%) NPV (%) PPV (%) NPV (%) PPV (%) NPV (%) PPV (%) NPV (%)
5 15 99 15 98 19 96 22 96 14 98
10 27 97 26 96 33 92 38 92 26 96
15 37 95 36 94 44 87 49 88 36 94
20 46 93 45 91 52 83 57 84 45 92
25 53 91 52 89 59 79 64 80 52 90
30 59 89 58 86 65 74 70 75 58 87
35 65 87 63 83 70 69 74 71 63 85
40 69 84 68 80 75 65 78 66 68 82
45 74 81 73 77 78 60 82 61 72 78
50 77 78 76 73 81 55 84 57 76 75
Predictive values of cut-offs for different prevalences of mild fibrosis (F<2); “Rule in” mild fibrosis
FIBC3 <–0.4 ABC3D <3 FIB4 <1.3 NFS <–1.433 ADAPT <6.3
Prevalence of mild fibrosis (%) PPV (%) NPV (%) PPV (%) NPV (%) PPV (%) NPV (%) PPV (%) NPV (%) PPV (%) NPV (%)
5 25 99 12 98 11 98 14 98 12 97
10 42 97 23 97 21 95 26 95 22 94
15 53 96 32 95 30 93 36 92 31 91
20 62 94 40 93 38 90 45 90 39 88
25 68 92 47 91 46 87 51 87 46 85
30 73 90 53 88 51 84 57 84 52 81
35 78 88 59 86 57 81 63 80 58 78
40 81 85 64 83 62 78 68 76 63 74
45 84 82 69 80 67 74 72 73 68 70
50 87 79 73 76 71 69 76 68 72 65
PPV, positive predictive value; NPV, negative predictive value.
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NAFLD has an estimated global prevalence of 25%, which is pre-
dicted to rise internationally.41–43 Associated mortality is directly
proportional to fibrosis stage, with patients at !F3 being at high-
est risk.2 Current non-invasive tests are suboptimal; therefore,
there is a clear need for better diagnostic biomarkers to detect
advanced fibrosis. Such tests could potentially aid diagnosis and
risk stratification, as well as facilitate clinical trial pre-screening
to reduce screening failure rates; all of which fall within the
BEST diagnostic context of use.11
At present, the reference standard to assess severity of NAFLD is
histological, using the semi-quantitative NASH CRN system.37
However, it is generally accepted that inter- and intra-observer
variability, and sampling error due to variability in the extent
of fibrosiswithin the liver,may impair the accuracy and reproduci-
bility of these histological assessments.37,44,45 This implies a
paradox that makes addressing the need for biomarkers all the
more challenging: the histological reference standard, against
which a biomarker is assessed, is inherently imperfect and unable
to produce a completely error-free classification with respect to
the presence or absence, or severity, of the target condition.
Semi-quantitative histological grading conflates anatomical distri-
bution of fibrosis with extent and imposes discrete categorical
staging bins onwhat are continuous variables like collagen deposi-
tion.37 This inevitably leads to discrepancies due to inter- and
intra-observer judgement, especially at the margins. It also blunts
sensitivity as semi-quantitative grades fail to recognisemodest dif-
ferences in severity that do not transition across predefined but
arbitrary categorical boundaries. This phenomenon is well illu-
strated by the breadth of disease that is encompassed by stage F3
fibrosis in the NASH CRN classification37 where histological
portal-portal, central-central and/or portal-central bridging is the
defining feature, yet no weight is given to density of collagen
deposition or the number of “bridging” septae. The situation
where an imperfect reference standard is used in place of a perfect
standard, introduces “imperfect gold standard bias”. This means
that the performance of the new test may be under- or over-
estimated and, even if it is in reality a better measure of disease,
it never has the potential to generate an AUROC >0.90.46 Although
not unique to liver histopathology, such situations are methodolo-
gically challenging to address.47
Cognisant of these challenges, we report measurement of
PRO-C3 levels in a large international cohort and incorporate
this measure into novel diagnostic models that outperform
numerous previously described blood-based tests that detect
advanced fibrosis.12–18
Utility of PRO-C3 as a single diagnostic biomarker
Although isolated parameters seldom exhibit an adequate level of
diagnostic accuracy and are unlikely to be a surrogate for the com-
plex diagnostic information provided by liver biopsy, we assessed
how PRO-C3 performed in this context of use. PRO-C3 performed
moderately as a biomarker of advanced fibrosis, comparable to
simple panels such as FIB4. Similarly, when used to screen
patients for clinical trial recruitment, PRO-C3 accurately identified
65% of cases that were histologically eligible for current phase III
trial recruitment (NASH with significant fibrosis). This moderate
performance as a diagnostic biomarkermay partially be explained
by the biological process that generate PRO-C3 during collagen
deposition, implying that PRO-C3 is most sensitive to active fibro-
genesis rather than static collagen accumulation. Supporting this
view, preliminary evidence suggests that PRO-C3may aid the eva-
luation of patients with active collagen turnover.48 In the present
study wewere unable to assess the value of PRO-C3 as a prognos-
tic test, that could be used to enrich studies for cases at greatest
risk of subsequent disease progression, or to monitor change in
disease severity.
FIBC3 and ABC3D performance for risk strati!cation of
!brosing steatohepatitis
In light of the moderate performance of PRO-C3 as a single
diagnostic biomarker, we assessed its value as part of a non-
invasive fibrosis panel composed of routinely measured clinical
and laboratory variables enhanced by inclusion of a single bio-
marker of fibrogenesis, PRO-C3. We report development and
validation of FIBC3. Whilst not the first panel to incorporate
these components, many of which are used within ADAPT,29
the current study benefits from detailed development and vali-
dation in a large, international patient cohort where careful
harmonisation of histological practice, coupled with central
reviewing of biopsies, has been undertaken to minimise the
potential impact of an imperfect reference standard. Overall, a
FIBC3 threshold of >-0.4 correctly identified fibrosis status in
77% of patients in the total cohort. However, the diagnostic
accuracy of ABC3D, a simplified panel, better adapted for use
in clinical practice (at the bedside) rivalled this model with an
accuracy of 75% and performed equivalently when assessed
across different clinical sub-populations and consistently out-
performed all other routinely used scores to which it has been
compared. Thus, in contrast to FIB4, NFS or the PRO-C3 based
ADAPT score, which require more complex formulas, this simple
model can be easily calculated by summing 5 easy to assess clini-
cal items, removing the need to access to a web-based calculator
or App to aid patient risk stratification. Furthermore, in contrast
to FIB4 or NFS, FIBC3 and ABC3D both have a single, optimised,
risk-threshold value, without “indeterminate” results which
would require further testing or liver biopsy to clarify disease
severity.19
In the validation cohort, FIBC3 performed best, correctly iden-
tifying 75% of patients, with ABC3D more or less equivalent
correctly identifying 72% of patients. In the full cohort of 449
patients, the FIBC3 model identified 254 patients as not having
advanced fibrosis (at a threshold of less than -0.4) of which 217
were correctly classified. Therefore, in this “low-risk cohort” the
FIBC3 model could have correctly avoided a liver biopsy in 85%
of patients. Applying the same analysis to ABC3D, 267 patients
were identified as ‘low-risk’ (score "3). In this cohort, 219 patients
were correctly staged, thus potentially correctly avoiding biopsies
in 82% of cases. Complex fibrosis panels also exist. They include
markers of matrix turnover, such as the Enhanced Liver Fibrosis
(ELF™) panel.18 However, a recent meta-analysis has reported
that ELF and NFS have very similar AUCs.49 Extrapolating this
observation to our data would imply that FIBC3/ABC3D (like the
NFS) had comparable, if not better, diagnostic value than the
more complex Fibrotest and ELF.
Potential to use ABC3D in primary care
The point performance of diagnostic tests in terms of PPV/NPV
are affected by pre-test probability, which reflects the preva-
lence of disease in a specific clinical setting. The prevalence of
advanced fibrosis in the current study cohort was 37% which
is much higher than would be expected in a primary care set-
ting. Indeed, population data, albeit limited, have found that






5.6% of the Dutch population have clinically significant fibrosis
based on a VCTE liver stiffness >8 kPa.50 Similarly, based on
VCTE thresholds !6.8, !8.0, and !9.0 kPa prevalence estimates in
the Spanish population were 9.0%, 5.8%, and 3.6%, respectively.51
These levels contrast sharply to a tertiary referral centre where
the prevalence of advanced liver disease is often well in excess
of 10%, and frequently nearer 30%.52–54 To model performance
across a range of settings, we calculated PPV and NPV for preva-
lence levels of advanced fibrosis from 5–50%. The NPV for both
FIBC3 and ABC3D were similar across a prevalence range of
5–15% and in excess of 90%. To explore performance of themodels
in specific patient subgroups, we split the cohort by gender, dia-
betes status, BMI, and patients with elevated or normal alanine
aminotransferase levels. FIBC3 and ABC3D maintained high NPV
in all subgroups, although sensitivity was lower in patients with
a BMI <25 and non-diabetics.
Strengths and limitations
FIBC3 and ABC3D were developed using an international cohort
of well-characterised, untreated patients with NAFLD, covering
a wide spectrum of disease severity. Liver biopsies were read by
expert histopathologists that belong to the EPoS consortium
pathology group, a group that undertook extensive harmonisa-
tion procedures for NAFLD pathological assessment and demon-
strated high kappa-value reproducibility.45 Moreover, half of the
biopsies across all sites were assessed centrally. While this
certainly reduces the reader-related variability, it is still depen-
dent on limitations intrinsic to histological classifications such
as the semi-quantitative nature of fibrosis scoring and on sam-
pling variability of the procedure. These limitations are common
to all biomarkers that use biopsy as the reference standard. Our
diagnostic model consists of readily available clinical and labora-
tory variables that are routinely determined in patients with
NAFLD in outpatient appointments. PRO-C3 levels were also mea-
sured in a central College of American Pathologists certified lab
by staff blinded to the clinical data, before results were sent to a
separate, independent centre for statistical analysis. Protein
finger print technology has been developed to produce a reliable
assay for PRO-C3 measurement.25 Our model, in comparison to
previous complex biomarker panels (e.g. ELF or Fibrotest)
includes only one variable that is not routinely measured in
a clinical setting. To minimise the effects of inter-observer varia-
bility in fibrosis staging, half the cohort across all centres had
centrally reviewed liver biopsies confirming high inter-observer
agreement.
Although we have taken measures to minimise inter-observer
variability in the histological scoring, and concordance between
liver pathologists was very good, an element of variability cannot
be fully excluded. We also acknowledge that percutaneous
liver biopsy is prone to sampling error leading to mis-staging
of disease severity. However, the key limitation, which is com-
mon to all biomarker studies that rely on histology, relates to
the nature of the semi-quantitative scoring systems and how
this conflates histological localisation of fibrosis and extent of
collagen deposition. We also acknowledge that AUROCs are
not perfect as a means for assessing diagnostic accuracy. ROC
curves attribute equal weight to false positives and false nega-
tives and do not provide information on predictive values,
which may be of greater value in a clinical setting.55 Our results
require further independent validation in other patient popula-
tions, to critically assess these models’ ability to discriminate
fibrosis stage.
In conclusion, both FIBC3 and ABC3D are simple indices
including accessible routine laboratory tests and a single marker
of collagen turnover. We have shown that both can accurately
differentiate mild to moderate fibrosis from bridging fibrosis
and cirrhosis in patients with NAFLD. Given that the ABC3D
model is much simpler to compute and can be done at the bed-
side, the ABC3D diagnostic index has the potential to be widely
used for the identification of patients with significant/active
fibrosing steatohepatitis who should undergo specialised liver
explorations, closer monitoring and possibly, specific therapies.
FIBC3 and ABC3D may also be used as pre-screening tools for
therapeutic trials, potentially helping to minimise histological
severity-related screening failure rates. However, this will require
further prospective validation.
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 Plasma cell-free DNA 
methylation: a liquid biomarker 
of hepatic!fibrosis
We recently reported dynamic epigenetic 
markers of fibrosis detectable in patients’ 
plasma that may have utility in non-inva-
sive diagnosis and staging of fibrosis in 
patients with chronic liver disease.1 Specif-
ically, we uncovered DNA methylation 
markers at the human PPAR! promoter 
detectable in circulating cell-free DNA 
(ccfDNA) that display differential methyl-
ation densities. Remarkably, PPAR! hyper-
methylation correlated with progression 
to cirrhosis in alcoholic liver disease (ALD) 
and with specific stages of liver fibrosis in 
non-alcoholic fatty liver disease (NAFLD). 
Furthermore, ccfDNA signatures were 
traced back to the molecular pathology in 
fibrotic liver tissue, providing a biomarker 
of the underlying pathological process 
and defining hepatocytes as the source of 
hypermethylated DNA found in plasma.1 
The original study posed several 
important outstanding questions: (1) 
Can ccfDNA methylation be used as a 
biomarker of fibrosis in liver diseases of 
other aetiologies? (2) Does the presence of 
hepatocellular carcinoma (HCC) alter the 
biomarker in plasma? (3) Does presence 
of fibrosis in other organs generate similar 
biomarker profiles?
In the present letter, we answer these 
questions and demonstrate the broader 
utility of DNA methylation at three CpG 
dinucleotides within PPAR! promoter in 
several new patient cohorts (figure 1A 
and table 1). Employing pyrosequencing 
we detect hypermethylation at all three 
CpGs in ccfDNA from a cohort of patients 
suffering from cirrhosis caused by chronic 
HBV infection (figure 1B–D). The level of 
hypermethylation resembled that found in 
patients with cirrhotic NAFLD and ALD in 
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our original study. However, since the HBV 
cohort was of another ethnicity to our 
original UK-based patients with NAFLD 
and ALD, we also measured methylation 
density in a Turkish NAFLD cohort, which 
was mirroring those detected in the HBV 
cohort. Our new data also demonstrate 
that presence of HCC with chronic liver 
disease does not alter the specificity of 
the DNA methylation markers for detec-
tion of liver fibrosis (figure 1B–D). As we 
had access to explant liver tissue from 
patients with NAFLD, HBV and HCC, 
we determined methylation densities in 
the liver (figure 1E–G). A high similarity 
was observed between the degree of DNA 
methylation at PPAR! gene promoter in 
ccfDNA and in the patient-matched liver 
tissues. We found a significant spread of 
values for DNA methylation in the healthy 
control ccfDNA, this being in contrast 
with our original UK-based study in which 
low-level methylation density was consis-
tent across individuals within the control 
Figure 1 (A) Schematic representation of human PPAR! gene promoter showing the positions 
of the differentially methylated CpGs 1, 2 and 3. (B–D) Plasma cell-free DNA methylation 
as determined by pyrosequencing at (B) CpG1, (C) CpG2 and (D) CpG3 within the human 
PPAR! gene promoter from control donors or patients with NAFLD, HBV, HCC or SSc. n, shows 
the number of individual patients within each cohort. DNA methylation was quantitatively 
measured and!expressed as a percentage. Error bars represent mean values±95% CI;! *P<0.05, 
**P<0.01, ***P<0.001. (E–G) Whole liver DNA methylation at (E) CpG1, (F) CpG2 and (G) CpG3 
within the human PPAR! gene promoter in patients with NAFLD, HBV and HCC. All methods are 
listed in the!online supplementary file.!cfDNA, cell-free DNA; HCC, hepatocellular carcinoma; 
NAFLD,!non-alcoholic fatty liver disease; SSc, systemic sclerosis.
Table 1 Characteristics of patient cohorts used in the study
Age (years) Gender (male/female) BMI (kg/m2) Diabetes!(%) ALT (IU/L) AST (IU/L)
NAFLD cohort 56 ± 7 10/3 29.8±3.2 69 33±23 54±36
Hepatitis B cohort 51±7 10/3 26.5±2.4 38 47±50 80±64
































55±14 10/20 26±3.8 12 (40%) 7.5±4 2 (7%) 11 (37%) 71.7±17 30!(100%) 11 (37%) 12 (40%)
Notes:!Viral hepatitis in HCC cohort: HBV-positive, n=8; HCV-negative, n=2; HBV-positive and HCV-positive, n=3. 
Data expressed as mean±SD or!median (range). 
BMI, body mass index; HCC, hepatocellular carcinoma; NAFLD,!non-alcoholic fatty liver disease; SSc, systemic sclerosis. ! 
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group. We are unable to explain this 
wider spread of methylation densities in 
the Turkish cohort, but cannot rule out an 
undetected liver disease in the apparently 
‘healthy’ controls that display elevated 
ccfDNA methylation.
We next determined if hypermethyla-
tion is specific to fibrosis of liver origin. 
To this end, we quantified ccfDNA 
methylation in a cohort of patients with 
limited and diffuse systemic sclerosis (SSc) 
who have various combinations of skin, 
lung and kidney fibrosis, but no hepatic 
fibrosis.2 All three CpG sites in SSc were 
relatively hypomethylated (figure 1B–D), 
with similar methylation densities between 
individual patients with SSc. All methods 
relating to the study are listed in ‘online 
supplementary materials and methods 1’.
This important validation study supports 
our original hypothesis that hypermeth-
ylation at the PPAR! gene promoter is a 
marker for fibrotic progression of chronic 
liver disease and holds true for viral, alco-
holic and metabolic disease aetiologies. As 
fibrosis in other organs does not generate 
a similar epigenetic signature, it is likely 
that the PPAR! hypermethylation specifi-
cally reflects a liver pathology. The ability 
to detect and quantify hypermethylation 
at the promoter of the PPAR! in ccfDNA 
as a new liquid biomarker that specifically 
reports the fibrotic progression of liver 
diseases of multiple aetiologies offers the 
potential for a cost-effective blood-based 
liquid biomarker of liver fibrosis.
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